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Chondroitin sulfate proteoglycans (CSPGs) are one major class of axon growth 
inhibitors that are upregulated and accumulated around the lesion site after spinal cord injury 
(SCI), and result in regenerative failure. To overcome CSPG-mediated inhibition, digestion 
of CSPGs with chondroitinase ABC (chABC) has been explored and it has shown promising 
results. chABC digests glycosaminoglycan chains on CSPGs and can thereby enhance axonal 
regeneration and promote functional recovery when delivered at the site of injury. However, 
chABC has a crucial limitation; it is thermally unstable and loses its enzymatic activity 
rapidly at 37 ºC. Therefore, it necessitates the use of repeated injections or local infusions 
with a pump for days to weeks to provide fresh chABC to retain its enzymatic activity. 
Maintaining these infusion systems is invasive and clinically problematic.  
In this dissertation, three studies are reported that demonstrate our strategy to 
overcome current limitations of using chABC and develop a delivery system for facilitating 
chABC treatment after SCI: First, we enhanced the thermostability of chABC by adding 
trehalose, a protein stabilizer, and developed a system for its sustained local delivery in vivo. 
Enzymatic activity was assayed by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and dimethylmethylene blue (DMMB), and conformational 
change of the enzyme was measured via circular dichroism (CD) with and without trehalose. 
When stabilized with trehalose, chABC remained enzymatically active at 37 ºC for up to 4 
weeks in vitro. We developed a lipid microtube-agarose hydrogel delivery system for a 
sustained release and showed that chABC released from the delivery system is still 
functionally active and slowly released over 2 weeks in vitro. Second, the hydrogel-
xvii 
 
microtube system was used to locally deliver chABC over two weeks at the lesion site 
following a dorsal over hemisection injury at T10. The scaffold consisting of hydrogel and 
chABC loaded lipid microtubes was implanted at the top of the lesion site immediately 
following injury. To determine effectiveness of topical delivery of thermostabilized chABC, 
animal groups treated with single injection or gel scaffold implantation of chABC and 
penicillinase (P‟ase) were included as controls. Two weeks after surgery, the functionality of 
released chABC and the cellular responses were examined by immunohistological analysis 
with 3B3, CS-56, GFAP and Wisteria floribunda agglutinin (WFA). The results 
demonstrated that thermostabilized chABC was successfully delivered slowly and locally 
without the need for an indwelling catheter by using the hydrogel-microtube delivery system 
in vivo. The results demonstrated that released chABC from the gel scaffold effectively 
digested CSPGs, and therefore, there were significant differences in CSPG digestion at the 
lesion site between groups treated with chABC loaded microtube-hydrogel scaffolds and 
controls. Third, a long term in vivo study (45 days) was conducted to examine axonal 
sprouting/regeneration and functional recovery with both a single treatment each of 
microtube loaded chABC or Neurotrophin-3 (NT-3), and a combination of them by using the 
hydrogel-microtube delivery system. Over the long term study period, the treated animals 
showed significant improvement in locomotor function and more sprouting of cholera toxin 
B subunit (CTB)-positive ascending dorsal column fibers and 5-HT serotonergic fibers 
around the lesion site.  
We demonstrated that this significant improvement of chABC thermostability 
facilitates the development of a minimally invasive method for sustained, local delivery of 
chABC that is potentially a useful and effective approach for treating SCI. In addition to that, 
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we demonstrated that combinatorial therapy with chABC and neurotrophic factors could 







1.1. STATEMENT OF PROBLEM 
Unlike in the peripheral nervous system (PNS) or embryonic nervous system, in the 
central nervous system (CNS) the severed axons fail to regrow through the lesion site, even 
though the spared neurons survive for years. 
There are approximately 255,000 people living with SCI in the United States and 
there are 12,000 new cases added each year. After injury to the central nervous system, the 
lesioned axons fail to re-grow and recover function (Schwab and Bartholdi, 1996). The 
extent of sensory and motor function loss after spinal cord injury (SCI) varies depending on 
the level of injury, and often results in permanent functional loss. Complete neurological 
recovery after SCI is experienced by less than 1% of patients. Since 2000, the most frequent 
category of spinal cord injury is incomplete tetraplegia (34.1%), followed by complete 
paraplegia (23.0%), complete tetraplegia (18.3%), and incomplete paraplegia (18.5%). The 
cost for treatment is up to $ 0.7 million per patient in the first year, and the lifetime cost is up 
to $ 3 million (National Spinal Cord Injury Statistical Center, 2008). The cellular and 
molecular mechanisms of the inflammation process, cell death, the mechanism of axon 
growth failure and receptor/targeting relationships are all active areas of research. While 
many groups are investigating a number of strategies to encourage axonal regeneration, a 
breakthrough clinical therapy has yet to be developed.   
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A challenge in the environment of the injured spinal cord is that the inhibitory 
molecules create a non-permissive environment for axonal regrowth and it results in a failure 
of axonal regeneration and complete functional recovery. chABC, which digests CS-GAGs 
on CSPGs, has shown promise as a therapeutic agent for SCI treatment (Yick et al., 2000; 
Krekoski et al., 2001; Bradbury et al., 2002) and CNS regeneration (Moon et al., 2001; Fox 
and Caterson, 2002; Pizzorusso et al., 2002). However there are crucial limitations and 
difficulties to be applied for clinical treatment; chABC is thermally very unstable and it loses 
its enzymatic activity quickly at body temperature. Therefore, multiple injection of chABC or 
mini-pump/catheter-mediated delivery system has been used to provide fresh chABC in vivo 
for long periods. However, these infusion systems are invasive and require much effort to 
maintain. In this study, an alternative strategy for chABC delivery in vivo is developed and 




 The central hypothesis of this dissertation is that the digestion of CSPG by 
chondroitinase ABC will promote axonal regeneration and functional recovery after SCI. The 
chABC digestion will remove the inhibitory effect of CSPGs limiting axonal regeneration 
after CNS injury and provide a permissive substrate for axonal outgrowth. We hypothesized 
that delivery of thermostabilized chABC using our slow and local delivery system will 
provide a sufficient amount of bioactive chABC to effectively digest CSPGs at the lesion site. 
Also, the delivery method will be more efficient than single injection of an equal amount of 
chABC to digest CSPGs, and it will enhance axonal sprouting/regeneration and induce 
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behavioral recovery. Therefore, our slow local delivery system could be an alternative 
method to current mini-pump/catheter delivery methods, which are invasive and infection-
prone because they are chronically implanted. We believe that a combination strategy of 
chABC and neurtophin-3 using the slow release delivery system will encourage even more 
axonal regeneration and functional recovery. 
It is important to achieve following design criteria to demonstrate our hypothesis: 1) 
thermostabilized chABC; 2) a delivery vehicle for slow release in a temporally controlled 
manner; and 3) a non-pump/single administration method in a spatially controlled manner. 
Strategies to solve these challenges are: 1) protein stabilizers; 2) lipid microtube and 
hydrogel mediated delivery system; and 3) a topical delivery model to the dorsal over 





 The overall purpose of the work described in this thesis is to develop an approach to 
successfully use chABC as a therapeutic agent. To overcome limitations of chABC treatment 
for SCI, it is necessary to improve thermostability of chABC and develop a delivery strategy 
for thermostabilized chABC in vivo. 
To meet this goal, the following objectives were set:  
1. To improve the thermal stability of chABC and develop a minimally invasive and 
slow delivery system. 
a. Determine ability of trehalose to improve thermostability of chABC in vitro.  
b. Develop a hydrogel and lipid microtube mediated delivery scaffold and 
evaluate functionality of post-released chABC in vitro. 
2. To supply thermostabilized chABC in vivo by implanting a hydrogel-lipid microtube 
delivery system with a topical delivery model and examine the functionality of 
released chABC and the cellular responses after SCI. 
a. Examine delivery efficiency of chABC by evaluating CSPG digestion two 
after implantation. 
3. To apply a combinatorial strategy using chABC and NT-3 to enhance therapeutic 
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Injuries trigger cellular and molecular signal cascades which upregulate inhibitors to 
axonal outgrowth and result in regenerative failure. Inhibition could be caused by myelin-
associated inhibitors, immune-response molecules, glial scars, inhibitory extracellular matrix 
(ECM) molecules, and the lack of trophic factors. One major class of growth inhibitors are 
chondroitin sulfate proteoglycans (CSPGs) that accumulate around lesion site after SCI.  
Studies have investigated CSPG-mediated inhibition to axonal regeneration. 
Chondroitinase ABC (chABC) digests glycosaminoglycan chains on CSPGs and can 
potentially overcome CSPG mediated inhibition and promote axonal sprouting/regeneration 
when delivered into lesion sites. However, chABC loses its enzymatic activity rapidly at 37 
ºC, necessitating the use of repeated injections or local infusions with a catheter and pump 
for days to weeks to digest the CSPGs being produced continuously. Maintaining these 
infusion systems is invasive and clinically problematic.  
To overcome the limitations of chABC therapy for clinical application, the following 
technical achievements must be met; stable bioactivity of chABC, a delivery system for 
sustained local delivery in vivo, and a non-pump/catheter administration. In this chapter, 
limitations that need to be overcome are described, and alternative methods and strategies to 





2.1 CELLULAR AND MOLECULAR RESPONSES AFTER SCI 
After injury to the central nervous system (CNS), the inflammation process is 
triggered, a series of cellular and molecular responses are cascaded and eventually glial scars 
are formed around the lesioned tissue (Fawcett and Asher, 1999). The failure of neurite 
regrowth and permanent functional loss result from these cellular events. To begin, 
macrophages and microglia, oligodendrocyte precursors, meningeal cells and astrocytes 
migrate into the lesion site. These cells produce inhibitory molecules, such as myelin-
associated glycoprotein (MAG), CSPGs and other proteoglycans, free radicals, nitric oxide, 
etc. The final form is a tightly interwoven glial scar formed around the lesioned site (Rudge 
and Silver, 1990). Macrophages from the bloodstream and microglia from the surrounding 
tissues are the first cells to arrive at the site, usually within a few hours after injury. They 
remove myelin debris, produce and release cytokines, recruit oligodendrocyte precursors and 
initiate reactive astrocytes. Inhibitory molecules are up-regulated and the injury site is 
exposed to non-permissive environment for axonal regeneration. Myelin-derived growth 
inhibitory proteins, such as NOGO, myelin associated glycoprotein (MAG), and 
oligodendrocyte-myelin glycoprotein (OMgp), contribute to the failure of optic nerve 
regeneration and spinal cord regeneration (Selles-Navarro et al., 2001). Oligodendrocyte 
precursors migrate from the surrounding tissue after 3-5 days and myelin debris contains 
myelin-associated inhibitory molecules: NOGO is present on the myelin surface and 
collapses the neuronal growth cone (Bandtlow et al., 1993); MAG is produced by and present 
in oligodendrocytes (Kastin and Pan, 2005); and OMgp is most recently identified and 
inhibits neurite outgrowth (Kottis et al., 2002).  
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If meningeal layers, which cover the CNS, are penetrated, meningeal cells migrate to 
cover the exposed area of CNS and form a barrier to axon regeneration. Astrocytes are the 
predominant and final structure of the astro-glial scar with ECM and ECM molecules. These 
cells divide in reactive form, slowly migrate into the injured area, fill the space caused by 
injury, and produce inhibitory molecules, such as chondroitin sulfate proteoglycans (CSPGs). 
This astro-glial scar acts as a barrier that prevents axons from passing through and inhibits 
axonal regeneration. CSPGs are over-expressed in extracellular matrix at the lesion site 
where reactive astrocytes are present, and ultimately form astro-glial scars that act as barriers 
to axonal outgrowth. CSPGs are generally accepted as potent inhibitory molecules of axon 
growth in the adult CNS. Therefore, recent studies focus on alleviating CSPG-mediated 
inhibition by delivering the enzyme chABC in vivo and to encourage axonal regeneration and 
functional recovery (Moon et al., 2001; Bradbury et al., 2002; Barritt et al., 2006).  
 
2.2 CSPG-MEDIATED INHIBITION AFTER SCI AND CURRENT TREATMENTS 
It is known that axons of the CNS cannot regenerate to form functional connections 
after injuries. However in the mid-1980s studies demonstrated that CNS neurons can 
regenerate their axons over long distances when a favorable environment is provided (So and 
Cho, 1989). Currently, many studies are investigating CSPG-mediated inhibition by 
removing the inhibitory nature of CSPGs through enzyme-mediated modification. These 
studies suggest that attenuating inhibitory effects of CSPG by chABC digestion enhances 
axonal growth and functional recovery. chABC is a bacterial lyase produced from the 
bactreum Proteus vulgaris that is able to digest CSPGs. The therapeutic significance of 
chABC has been demonstrated in studies that delivered this enzyme to enhance nerve 
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regeneration (Bradbury et al., 2002; Barritt et al., 2006). However there are several 
limitations to clinical treatment before implementation can occur. 
 
2.2.1 CHONDROTIN SULFATE PROTEOGLYCANS 
CSPGs consist of a core protein and glycosaminoglycan (GAG) chain that are 
covalently linked to form a brush-like structure (Fig. 2.1). The GAGs are linked to the core 
protein by a trisaccharide composed of two galactose and one xylose residue. GAG is made 
of repeating disaccharides containing either two modifier sugars, glucuronic acid (GlcNAc) 
or galactosamine (GalNAc) and an uronic acid (glucuronate or iduronate). These chondroitin 
sugars can have over 100 individual sugar molecules and each can be sulfated in various 
positions and quantities. Figure 2.2 shows that chondroitin sulfate glycosaminoglycans 
(CSPG) have structural diversity (e.g. chondroitin-4-sulfate (∆glcA-β1,3-4S-galNAc), 
chondroitin-6-sulfate (∆glcA-β1,3-6S-galNAc), chondroitin-2,6-sulfate (∆2S-glcA-β1,3-6S-
galNAc), dermatan-4-sulfate (∆iduA-α1,3-4S-galNAc), etc.) (Gilbert et al., 2005).  
CSPGs are upregulated after injury in the CNS and become a major contributor to the 
failure of axonal regeneration (Pindzola et al., 1993; McKeon et al., 1995; Fitch and Silver, 
1997; Asher et al., 2000; Asher et al., 2002; Jones et al., 2003; Tang et al., 2003). CSPGs 
also regulate neurons during development by defining barriers in CNS structures: 
perineuronal nets (PNNs) (Matthews et al., 2002) in the brain and spinal cord, the roof plate, 
a putative axon barrier, of the spinal cord and optic tectum (Snow et al., 1990a), and the 
hippocampus (Wilson and Snow, 2000). Studies have shown that neurite outgrowth is 
inhibited by CSPGs in vitro (Snow et al., 1990b; McKeon et al., 1991; Snow and Letourneau, 
1992; Condic et al., 1999; Hynds and Snow, 1999; Snow et al., 2001; Johnson et al., 2002) 
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and in vivo after injury of optic nerve (Selles-Navarro et al., 2001) or the dorsal root entry 
zone (Zhang et al., 2001). However, the precise contribution of different CSPGs to CSPG-
mediated inhibition in the CNS and the mechanism of cellular transduction of the inhibitory 
signal mediated by CSPGs are not clear. Because CSPGs have a significant structural 
diversity, the nature and profile of CSPG deposition patterns have been recently investigated 
(Jones et al., 2003; Properzi et al., 2005). Specific CSPGs are differentially over-expressed in 
astro-glial scar after injury and CSPGs have varying degrees of inhibition (Gilbert et al., 
2005).  
After spinal cord injury, glial scars present a physical barrier and also produce 
repulsive molecules such as CSPGs. This effect of CSPG-mediated inhibition can be 
attenuated by applying chABC, which is an enzyme degrading CS-GAG (Snow and 
Letourneau, 1992; Zuo et al., 1998; Krekoski et al., 2001). Therefore, enhanced axonal 
regeneration can be achieved by removing CSPGs or the GAG side chains of CSPGs with 
enzymes, such as chABC.  
 
2.2.2 CHONDROITINASE ABC  
chABC is one of a class chondroitinases and has a molecular weight of 120 to 145 
kDa as determined by gel filtration (100 k Da in the SDS-PAGE). It is produced from 
bacterium Proteus vulgarism and there is no mammalian equivalent (Ryan MJ, 1994). 
chABC cleaves chondroitin, chondroitin-4-sulfate (C-4-S), chondroitin-6-sulfate (C-6-S), 
dermatan sulfate (DS) and hyaluronan GAGs by β-elimination of 1,4-hexosaminidic bonds 
into disaccharides and tetrasaccharides, yielding protein enriched core molecules with a 







Figure 2.1. Structure of chondroitin sulfate proteoglycan (CSPG). (A) versican, 
a large CSPG belonging to the lectican family and (B) decorin, a small CSPG 
of extracellular matrix.  




Figure 2.2. Schematic structure of various CSPGs and hyaluronan. Figure 
from Gilbert et al., 2005.  
 
 
The chABC is isolated from Proteus vulgaris contain two distinct eliminases, endolytic 
(chABC I) and exolytic (chABC II) lyases (Hamai et al., 1997). chABC is commercially 
available and the commonly used chondroitinase enzymes are provided by Seikagaku 
Corporation (Japan) as “chondroitinase ABC (chABC I + chABC II)” and “chondroitinase 
ABC, protease-free (chABC I)”. Usually the highly purified chABC, “chondroitinase ABC, 
protease-free”, has been used for in vivo study and is used in this study. 
chABC I is a 997 amino acid residue monomeric protein that degrades its substrates 
to tetrasaccharides and disaccharides. The complete crystal structure of chABC I has been 
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determined to contain three domains: the N terminal, central, and C terminal domains. The 
overall dimensions of chABC I is 115 Å × 70 Å × 55 Å and is folded into the three distinct 
domains (Huang et al., 2003). This structure shows overall similarity to other GAG lyases 
with additional domains on the N terminal. About 400 amino acid residues are in the C 
terminal domain also shows a homology to chondroitinase AC (cAC; two domain) (Fethiere 
et al., 1999) and bacterial hyaluronidases (Li et al., 2000). The role of this C-domain is not 
clear, however, one loop in this domain acts as a substrate-binding site. The N terminal 
domain consists of residues 25-234 and is the most flexible in chABC I compared to others. 
The N-domain has a common topology to other ligand-binding domains, particularly the 
carbohydrate-binding domains of xylanases and glucanases (Lo Conte et al., 2000).  The 
central domain (residues 235-617) contains 15 α-helices and is most likely the catalytic site. 
The α-helix domain shows very similar sequence identity to the catalytic domains of cAC 
and hyaluronidase. The active site of chABC I, as informed by superimposition with cAC 
structure, has been investigated (Prabhakar et al., 2005a; Prabhakar et al., 2005b). However, 
the active site has not been clearly defined and it is still unknown as to why chABC quickly 
loses its enzymatic function at body temperature. In addition, a strategy has not been 





Figure 2.3. Ribbon drawing of chondroitinase ABC I (figure from 
(Huang et al., 2003)); the N-terminal (green), middle catalytic (blue) 




chABC has the widest substrate specificity; therefore, it has been used widely, 
including as a therapeutic agent for SCI. Treatment with chABC has shown promising results 
with various CNS applications, such as regeneration of ascending sensory neurons and 
descending corticospinal tract axons in the spinal cord (Bradbury et al., 2002), sensory 
neurons in the dorsal root entry zone (Steinmetz et al., 2005), and retinal ganglian cell axons 
in the tectum (Tropea et al., 2003). Therefore, chABC offers a potential treatment strategy for 
neural injury.  
 
2.2.3 DELIVERY OF CHONDROITIANSE ABC FOR AXONAL REGENERATION 
AND LIMITATIONS 
chABC promotes axonal regeneration and functional recovery after CNS injury (Yick 
et al., 2000; Moon et al., 2001; Bradbury et al., 2002; Yick et al., 2003; Chau et al., 2004) 
and developmental disease (Pizzorusso et al., 2006). It promotes neurite sprouting in intact 
and injured spinal cords (Barritt et al., 2006). Most groups deliver chABC via intrathecal 
injection varying the infusion frequency from every other day to every other week, for time 
periods ranging from 2 weeks up to 6 weeks (Chau et al., 2004; Caggiano et al., 2005; Houle 
et al., 2006; Huang et al., 2006). Some groups inject chABC in combination with other 
therapeutic agents (Tropea et al., 2003) or with transplantation, such as that of E14 fetal 
spinal cords (Kim et al., 2006) or autologous peripheral nervous grafts (Houle et al., 2006), to 
obtain a synergistic effect.  
However, there are several limitations and difficulties to these methods. chABC is 
thermally very sensitive at body temperatures, so after 1 hour of incubation at 37 ºC it 
quickly loses 50% of its enzymatic activity (by Morgan-Elson reaction). It loses most of its 
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enzymatic function after a day. In addition, CSPGs are upregulated and accumulate in the 
extracellular matrix around the injured site up to at least 2 weeks after the primary injury. 
Therefore, most researchers continuously infuse chABC intrathecally through mini-
pumps/catheters to maintain a supply of fresh enzyme. Another limitation is the diffusion of 
chABC. Most of these deliveries are performed intrathecally with a catheter, so it is hard for 
chABC to diffuse into deep regions of the tissue. Because intrathecal delivery allows the 
drug to flow through intrathecal space, the drug washes away quickly and does not last a long 
time in the target area. Also, because of this drug diffusion, the concentration immediately 
dilutes to significantly low concentrations, so high concentrations (from 2U/ml to 1000U/ml) 
are needed to compensate. This is a problem for chABC. Because this enzyme is very 
expensive, it is costly to apply therapeutically in high concentrations. As we can see, there 
are several problems to overcome; specifically there is a compelling need to control chABC 
delivery both spatially and temporally.  
 
2.3 THERAPEUTIC STRATEGIES TO IMPROVE THERMAL STABILITY OF 
PROTEINS 
Thermal stabilization of protein has many practical applications in research and 
industry. Since chemical reactions are generally faster at higher temperatures, enzymes, 
which are stable at higher temperature, would yield a more efficient process (Schoemaker et 
al., 2003; Unsworth et al., 2007). Also in the laboratory, thermally stable proteins/enzymes 
are easier to store or handle. Many studies have been conducted to engineer thermostability 
of proteins and there are two general strategies for protein engineering to improve the 
thermal stability of proteins or enzymes (Bae et al., 2008): rational design and directed 
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evolution. Another strategy is to add cosolvents for modifying solvent environment (Cleland 
and Wang, 1990). 
 
2.3.1 PROTEIN ENGINEERING  
In rational design, precise changes on amino acid sequence are designed from 
detailed knowledge of the structure and function of the protein by using site-directed 
mutation (Chen, 1999; Eijsink et al., 2004). It is generally inexpensive and easy, however the 
detailed structure of a protein is often not available and even with the detailed information it 
is difficult to predict the effect of mutation on protein functions. The other strategy, directed 
evolution, involves generation of random mutations in the protein sequence, and does not 
require information as to how the structure is related to function (Kuchner and Arnold, 1997; 
Eijsink et al., 2005). This mimics natural evolution; random mutation is applied to a protein, 
selected to pick desirable variants, and further rounds of mutation and selection are applied. 
This directed evolution approach is hard to predict the results of stability and functionality, 
and it requires an effort to narrow down best candidate. Random or rational 
engineered/directed mutation is generated by screening a library of variants to produce a 
stable variant. Many mutations that result in the most stable variant would have been difficult 
to predict by rational design and the results of directed evolution are often better than rational 
results. However these two techniques are not mutually exclusive and recently researchers 
engineer proteins in combination of these methods to render desired changes (Eijsink et al., 
2004).  
Enzyme stability can be improved by rational design, directed evolution or in 
combination. Surface position is good candidate for optimizing protein stability (Martin et al., 
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2002). Surface or near-surface interactions are important for protein stability. However, very 
limited number of mutants can lead to an increase of stability and do not affect functionality. 
Random method has been used to generate mutation and it can lead high stability, but some 
of which are not easy to define rationally. Therefore, recently semi-rational method is 
frequently used. To apply for our case, chABC, several charged residues could be selected 
from the surface of the 3D structure (Prabhakar et al., 2005a; Prabhakar et al., 2005b), except 
active residues, and randomly mutate these residues and find optimized mutants. The stability 
of mutated chABC can be determined by 2D structure (circular dichroism) or 3D (X-ray 
crystal structure), and the functionality by enzymatic activity assays, such as, SDS-PAGE, 
western blotting, DMMB and HPLC method.  
 
2.3.2 USAGE OF COSOLVENTS IN AQUEOUS SYSTEM 
The other approach to stabilize protein is through addition of cosolvents. Cosolvents 
can be broadly categorized into the following: sugars and polyols (sugar alcohol), amino acid, 
amines, salts, polymers and surfactants. The level of stabilization by different cosolvents 
varies for particular proteins. Therefore, a cosolvent that stabilizes one protein/enzyme may 
not stabilize another (Hatti-Kaul and Mattiasson). Sugars (Carninci et al., 1998) and polyols 
(Xie and Timasheff, 1997a) are the more commonly used nonspecific protein stabilizers. 
Amino acids are also commonly used as stabilizer or osmolytes (Taneja and Ahmad, 1994; 
Remmele et al., 1998). The cosolvent may affect both the structural stability and activity of 
protein. Sugars and polyols always have been shown to enhance the thermal stability of 
proteins, but some amino acids have been found to destabilize the protein. The effects of salts 
also depend on pH of the medium and their chemical nature (Rishi et al., 1998). Therefore, 
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sugar or polyol are safe candidates as cosolvents. Often higher concentration of protein 
increases its own stability, however high concentration could lead a chance of protein 
aggregation. Surfactant is often used to reduce protein aggregation or protein surface 
adsorption, however the concentration of surfactants need to be carefully decide to avoid side 
effects (Faustino et al., 2009).  
 
2.3.2.1 TREHALOSE AS A PROTEIN STABILIZER 
Among various cosolvents, trehalose shows an exceptional improvement of thermal 
stability of protein (Kaushik and Bhat, 2003). Trehalose accumulates dramatically during 
heat shock and stationary phase in many organisms, then enhances thermo-tolerance and 
reduces aggregation of denatured proteins. Therefore, trehalose is a good candidate as a 
stabilizer for chABC. It has not been found in mammals, however this improves the tolerance 
of mammalian cells to desiccation and cryopreservation in vitro. This approach would be 
more convenient than the engineering protein.  
Trehalose is found in nature as a disaccharide, two α-D-glucose molecules with the 
alpha bond in a 1α→1 glycosidic linkage (α-D-glucopyranosyl(1→1)-α-D-glucopyranoside). 
It is commonly used as a sweetener in food and as a cryopreservation additive. It is also 
known as an exceptional protein stabilizer, providing protection to biological materials 
during dehydration and desiccation (Sampedro et al., 1998). It promotes survival under 
extreme heat by stabilizing proteins in order to retain their conformation and suppresses the 
aggregation of denatured proteins (Singer and Lindquist, 1998). Further, trehalose stabilizes 
labile proteins during lyophilization (Zhang et al., 2009), protects enzymatic activity, such as 
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with RNase A, lysozyme, cytochromes during exposure to high temperatures in solution, and 
in a freeze-dried state (Kaushik and Bhat, 2003).  
 
 
Figure 2.4. Structure of trehalose. 
 
2.3.2.2 THE POSSIBLE MECHANISMS OF TREHALOSE STABILIZATION OF 
CHABC 
As described previously, trehalose has unique properties with exceptional ability to 
protect biological materials under extreme conditions (Cottone et al., 2005; Hedoux et al., 
2006).  Many studies have been conducted to understand the mechanism of trehalose and 
possible mechanisms have been proposed, however the molecular mechanism of trehalose 
stabilization is poorly understood (Hedoux et al., 2009).  There are several hypotheses to 
explain the mechanism of trehalose efficiency: 1) water replacement model (Crowe et al., 
1984), 2) preferential hydration hypothesis (Arakawa and Timasheff, 1983), 3) vitrification 
of solutions (Green et al., 1989) and 4) the influence on the water tetrahedral hydrogen-bond 
network (Branca et al., 1999). However, the molecular mechanism probably depends on the 
nature of applied stresses.  
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The preferential interaction theory was proposed by Arakawa and Timasheff in 1983. 
They observed that bovine serum albumin and lysozyme were preferentially hydrated in 
amino acids. Preferential interaction is also stated as preferential binding of the cosolvent or 
preferential exclusion (preferential hydration). The cosolvent chemical potential perturbation 
by the protein is the driving force of preferential interaction, which causes change of the 
amount of water in contact with protein (Timasheff, 2002). Studies showed that trehalose 
stabilizes the folded structure of proteins in solution due to greater preferential hydration of 
the unfolded state compared to the native state (Xie and Timasheff, 1997b). Therefore, the 
mechanism seems to be opposite from the stabilization mechanism in the dried state, which is 
water replacement. Sugars generally protect proteins from dehydration by preventing the 
decrease of spacing through hydrogen bonding to the dried protein surface, serving as a water 
substitute (Carpenter et al., 1993). Like this, the mechanism of stabilization can be different 
under different applied stress conditions.   
The primary mechanism by which trehalose is likely to affect the stability of the 
proteins is by increasing the surface tension of water around the proteins due to hydrogen 
bond formation between the hydroxyl groups of trehalose and water. In solution, trehalose 
stabilizes RNase A by increasing the surface tension of the trehalose solution, leading to the 
preferential hydration of the protein (Xie and Timasheff, 1997a). Surface tension of trehalose 
solutions increases linearly with increasing trehalose concentration (Kita et al., 1994), and 
there is a strong correlation between surface tension and increase in Tm (Jai et al., 2003).  
Increasing solvent surface tension necessitates more energy to form a cavity in order to 
increase the surface area of proteins upon denaturation. In fact, other protein stabilizers, such 
as polyols and carboxylic salts (Kaushik and Bhat, 1999) show a correlation between surface 
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tension increase and enhanced protein thermal stability. Studies also have shown that the 
dynamic fluctuation of polar side chains at the solvent-protein interface is reduced in the 
presence of trehalose (Hedoux et al., 2009). The increased surface tension or the limited 
exposure of hydrophobic groups to the water molecules leads to preferential hydration, 
resulting in the stabilization of the tertiary structure of protein (Timasheff, 2002).  
 
2.3.3 PROTEIN STABILIZATION BY PEGYLATION  
PEGylation describes a process of covalent conjugation with polyethylene glycol 
(PEG) polymer chains to biological molecules. PEG (Figure 2.5) manufactured by 
polymerization of ethylene oxide with water, ethylene glycol or ethylene glycol oligomers 
and various molecular weights of PEG can be prepared by modulation of the polymerization 
reaction. In 1970s, Aluchowski et al. studied a pioneering method of PEG conjugation 
(Abuchowski et al., 1977). In the study, methoxypolyethylene glycol was covalently attached 
to bovine serum albumin and it lost its immunogenicity and the potential of PEG conjugation. 
After this successful study, a number of studies followed and PEG has been applied to 
several biological therapies and success have been achieved in parallel with improvements of 
the PEG properties (Veronese and Mero, 2008). PEG is a biologically favorable molecule, a 
non-toxic and non-immunogenic molecules approved by the US FDA for internal use. 
PEGylation has been well established in the clinic and there are many PEGylated 
pharmaceuticals on the market, such as Pegasys (PEGylated interferon alpha), Oncaspar 
(PEGyleated L-asparaginase), Neulasta (PEGylated granulocyte colony-stimulating factor), 





Figure 2.5 Poly(ethylene glycol) 
Proteins/enzymes are delicate molecules and easily denatured or deactivated.  
PEGylation is can be applied to these therapeutic agents to modify or improve their stability, 
degradation by proteases or immunogenicity, and degree of renal excertion. The covalently 
attached PEG chains change the physical and chemical properties of the agents. Several PEG 
chains are attached on the surface of agents and result in increasing the molecular weight and 
creating water cloud surrounding the PEGylated agents by hydrogen bond formation between 
ether-oxygen in PEG (Figure 2.6). The modification improves pharmacokinetics of drugs: 
shielding the PEGylated agents from the host‟s immune system reduces immunogenicity and 
antigenicity and increases stability. It also provides high solubility in both aqueous and 
organic solvent, high mobility in solution, high hydration increasing hydrodynamic size in 
solution, and increases of the retention time in blood (Israelachvili, 1997). Due to the 
pharmacokinetic benefits of PEGylation, therapeutic proteins, peptides and antibody 





Figure 2.6 Schematic of PEGylated protein. The circles represent the 
water cloud recruited by the ether-oxygen groups of the PEG polymer.  
Figure from Veronese and Mero, 2008. 
Hydroxyl group of the PEG terminal can react with the various protein amino acid 
residues. Since amino groups are present in every protein, generally at the surface and 
exposed to the solvent, it is the most exploited residue for PEGylation by alkylation or 
acylation. Amino group modification can negatively affect surface properties of the protein 
and in some cases the modification decreases enzymatic/biological activity (Banci et al., 
1990; Greenwald et al., 2003). Modifying cysteine thiol residue by formation of thio-ethers 
or disulfides allows site-specific conjugation. Generally cysteine residues are involved in 
catalysis or disulfide bridges, so available free cysteine residues are rarely present. Therefore, 
sometimes this residue is genetically introduced in a desirable position for convenient 
applications (Kopchick et al., 2002). Disulfide-linked PEG conjugation can be a reversible 
modification and it allows a releasable PEGylation under mild reducing conditions 
(Woghiren et al., 1993). Similarly customized triggering moiety by enzymatic reaction, 
hydrolysis, or linker self-immolation cleaves the link and releases PEGylation, regenerating 
native agents and preserving its bioactivity. Recent reports demonstrate that the customized 
linkers of cytokines, peptide hormones, enzymes or receptor proteins are released under 
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physiological conditions and at specific and therapeutically useful rates (Filpula and Zhao, 
2008).  
Other amino acid residues, such as arginine (Veronese and Mero, 2008), glutamine, 
the alcohol group of serine and threonine, and the phenolic group of tyrosine (Orsatti and 
Veronese, 1999) are usable sites for PEG conjugation. For glutamine residue conjugation, the 
enzyme, transglutaminase, is used because there is no chemical method (Sato et al., 1996) 
and this glutamine-PEGylation is very specific (Fontana et al., 2008). However, because of a 
lack of specificity (arginine) and harsh reaction conditions (serine and theronine) other 
methods still need to be improved for therapeutic applications.   
Since covalent binding is involved in PEGylation, and several PEG chains are usually 
linked on the surface, the size and conformation of the agents are changed. Also, there is a 
possibility that conjugated PEG polymers can block the binding sites and active sites 
resulting in loss or damage of the agent‟s bioactivity. Therefore, the mass, number of chains 
and link positions need to be investigated for each case to maintain its bioactivity. To avoid 
these complications, genetically engineered proteins can be used: a genetic variant of amino 
acids is inserted at a site far from biologically active site and used for a residue to PEG 
conjugation (Kopchick et al., 2002).  
PEGylation has many advantages and some disadvantages to be used as a protein 
stabilizer. In our case with chABC, it would not be an ideal method for several reasons. 
Linked PEG chains can mask catalytic site of chABC, however exact positions of the site are 
still not clear and the mechanism of deactivation of chABC enzymatic activity is also 
unknown. Therefore, it is not easy to design a relevant PEG polymer conjugation for chABC 
to thermostabilize its enzymatic activity. Additionally, chABC is a relatively large molecule 
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and the increased size of chABC with PEGylation will result in limited diffusion through the 
nerve tissue. Therefore, we decided to use cosolvent in this study. 
 
2.4 THERAPEUTIC STRATEGIES FOR CONTROLLED RELEASE OF AGENTS BY 
DELIVERY CARRIERS 
The formulation of macromolecular agents, such as proteins, enzymes, and DNA in 
drug delivery systems is widely investigated due to the increased needs as therapeutics. 
Various carriers have been used for the efficient delivery of agents for different therapeutic 
purposes. For slow and local delivery of chABC after SCI, it is important to control 
temporally and spatially the amount of protein delivered over a period of time. Also, the 
delivery vehicle is able to maintain bioactivity of the agents over the period of time. The 
implanted vehicle itself and by-product of degraded vehicle should not induce significantly 
increase of inflammation response or aggravation of immune responses. Currently major 
delivery method of chABC for clinical and in vivo application to treat SCI is intrathecal 
injection through the implanted catheter with mini-pump or syringe (Bradbury et al., 2002; 
Barritt et al., 2006). This delivery system consists of two parts: 1) an infusion pump or an 
external catheter end implanted under the skin on the back of the animal, and 2) catheter 
inserted in the lesion site. However the internal catheter end is chronically implanted, and 
human cases have reported that intrathecal catheter-tip causes inflammatory mass (Peng and 
Massicotte, 2004), and surgical site infection (Burgher et al., 2007). Also an insoluble gelatin 
sponge and gelfoam containing chABC was used to treat SCI (Yick et al., 2003). In this 




2.4.1 POLYMER NANOPARTICLE 
Various delivery vehicles are used to deliver drugs into the CNS and PNS, such as 
liposomes, polymer nanoparticles and lipid microtubules. In order to locally deliver drugs for 
spinal cord treatment, PLGA nanoparticles and lipid microtubules could be considered for 
sustained delivery. Our laboratory has used both vehicles for in vivo sustained drug delivery. 
PLGA is a biocompatible and biodegradable polymer and is approved by US Food and Drug 
Administration for human use. PLGA nanoparticle have been used for sustain release of 
encapsulated agents (Shive and Anderson, 1997). The double emulsion method is used to 
make PLGA nanoparticles and is simple and takes a relatively short time, a total of 3 days. 
Additionally, it is easy to store in nanoparticle powder form at -80 ºC after lyophilizing. 
However during the double emulsion procedure, the releasing agent, such as protein, can be 
exposed to organic solvents (ex. Dichloromethane) and high temperatures. Without co-
encapsulation of acid-neutralizing base, the pH is predominantly below pH 5.8 (detection 
limit in this paper) (Li et al., 2005). Therefore proteins undergo physical denaturation and 
chemical degradation during fabrication (Sah et al., 1999; Kim et al., 1999) and 
unpredictable release profiles often occur, such as a burst effect or incomplete release (Kim 
et al., 1999). Only a few proteins have shown the ability of controlled delivery from PLGA 
spheres (Kim et al., 2005).  
 
2.4.2 LIPID MICROTUBES 
Lipid microtubes are also capable of the slow release of protein or bio-agents for in 
vivo application. It spontaneously forms hollow and open-ended cylinders (Schnur, 1993) 
with 0.5 µm of the average inner diameter and the lengths of the cylinders depend on the 
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cooling rate (Thomas et al., 1995; Meilander et al., 2001). Microtubes have a high aspect 
ratio and it allows for a large storage volume and they are stable in physiological medium at 
37 ºC (Spargo et al., 1995) for prolonged a period of time. The fabrication process takes a 
relatively long time, a total of 15 days, and microtubes need to be prepared freshly. However, 
there is no toxic procedure for proteins, which could cause denaturation or degradation, 
during the fabrication process. Microtubes show a stable and continuous release profile and 
could be used as sustained delivery vehicles for proteins, such as neurotrophic factors (Jain et 
al., 2006), and even nucleic acids (Meilander et al., 2003). It is also easy to combine with 
hydrogels to support a scaffold for in vivo application and non-inflammatory (Rudolph et al., 
1992; Meilander et al., 2001). Lipid microtubes are injectable either by themselves, or when 
embedded in thermo-reversible hydrogels as reported in Jain et al. (2006) for localization. 
The study showed that an agarose hydrogel scaffold embedded by BDNF loading lipid 
microtubes was implanted into a spinal cord cavity and led to the reduction of the 
inflammatory response and enhanced axonal infiltration into the scaffold.  
The molecules are released through the ends of microtubes, and a mathematical 
model of release profile of proteins has been developed previously in our laboratory 
(Meilander et al., 2004). The release of proteins can be predicted with the molecular weight 
and protein concentration. The slow release of agents can be modified by controlling the 
length of microtube, type of gel, and gel concentration for desire delivered amount of agent 






2.5   PHARMACOLOGICAL STRATEGIES FOR SCI 
2.5.1 NEUROPROTECTIVE THERAPY TO TREAT ACUTE SCI 
 There are limited therapies for SCI and no effective treatment to reduce damage and 
to promote functional recovery (Martinon and Ibarra, 2008). Methylprednisolone (MP), 
which is a synthetic cortico-steroid and typically used for anti-inflammatory effect, has been 
used as a drug for acute SCI in humans for three decades with limited clinical support, and it 
is the only available drug for acute SCI in human. However it is based in large part on 
physiological hypotheses and its beneficial effect on the neurological recovery of patients has 
not been clearly proven (Hugenholtz, 2003). The effect of MP administration in patients with 
acute spinal cord injury was clinically examined by National Acute Spinal Cord Injury Study 
I, II and III (NASCIS) (Bracken et al., 1984; Bracken et al., 1985; Bracken et al., 1990; 
Bracken et al., 1992; Bracken et al., 1997; Bracken et al., 1998). In NASCIS II, a patient sub-
group received a 24 hour high-dose infusion of MP within 8 hours following acute SCI 
showed improved neurological recovery (Bracken et al., 1990). Therefore within 8 hours 
after injury and high-dose infusion (typically 30 mg/kg bolus injection and 5.4 mg/kg/h 
following injection over 23 hours) has been an implied standard for clinical treatment. The 
high-dose of MP causes several side effects, such as impaired lung capacity and the higher 
incidence of sepsis and pneumonia. Compelling evidence of its efficacy is not yet conclusive 
(Gerndt et al., 1997).   To minimize the side effects related to systemic delivery, localized 
delivery methods have been developed: previously, our group developed a sustained and 
local delivery method. MP was delivered on the top of the lesion site by agarose hydrogel 
delivery system embedded with biodegradable polymer nanoparticles and showed effective 
diffusion through the spinal nerve tissue and significantly reduced early inflammation 
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(Chvatal et al., 2008; Kim et al., 2009). However, still there is the confusion with MP utility 
for acute SCI and MP should be used with caution, particularly if infusion goes longer than 
24 hours. 
 A wide range of other pharmacological treatments have also been evaluated and in 
some cases have shown potential with promising results. Cyclooxygenase (COX) is an 
enzyme that is involved in prostanoids formation. Pharmacological COX inhibitor acts as an 
anti-inflammatory agent reducing inflammation and pain, and some selective (indomethacin; 
(Pantovic et al., 2005)) or non-selective (NS-398 to COX-2; (Hains et al., 2001)) COX 
inhibitors promoted neuroprotection. Immunophilins (IPs) are peptidyl-prolyl cis-trans 
isomerases and some IPs are receptor for immunosuppressive drugs such as cyclosporine A 
and FK506 (Sosa et al., 2005). Drugs inhibits the activity of calcineurin, which is a protein 
phosphatase and activates the T cells of the immune system, and the drug binding can 
promote neuroprotective effect and results in inducing neuroregeneration (Ibarra and Diaz-
Ruiz, 2006).   
Oxygen radical-induced lipid peroxidation (LP) plays an important detrimental role in 
acute CNS injury. Therefore, several therapeutic strategies have been applied to diminish its 
effects (Hall et al., 1992). As previously mentioned, MP has been used for human SCI and 
lazaroids, 21-aminosteroids, also show significant antioxidant effects without the same side 
effects of MP (Hall and Springer, 2004). Tirilazad, one of lazaroids, was also examined in 
the NACIS III and tirilazad treated patients showed slightly better neurological recovery, but 
not significantly higher than those treated with MP (Bracken et al., 1997). Therefore, there is 
a possibility for the use of tirilazad in humans bearing FDA approval.  
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Calpains are a family of calcium-dependent, non-lysosomal cysteine proteases. 
Hyperactivation of calpains follows traumatic brain injury or spinal cord injury due to Ca2+ 
influx and it leads irreversible cell damages such as breakdown of cytoskeleton and plasma 
membrane and damage of ion channels, cell adhesion molecules and surface receptors. 
Therefore, calpain can cause neural cell apoptosis after SCI (Ray et al., 2003). Highly 
specific inhibitor to calpain for therapeutic use has been investigated such as E-64-d (Zhang 
et al., 2003) and leupeptin (Momeni and Kanje, 2006), and these inhibitors demonstrated 
neuprotective ability in models of SCI. 
Besides those therapeutic strategies, there are a number of pharmacological therapy 
targets, such as apoptosis inhibitors, steroid hormone and soldium channel blockers, and 
NMDA and AMPA-Kainate receptor antagonists (Martinon and Ibarra, 2008).  
 
2.5.2 NERVE GROWTH FACTORS: NEW POSSIBLE THERAPEUTIC STRATEGY 
Several neurotrophic factors induce neuroprotection and promote axonal outgrowth 
and functional recovery in traumatic injuries to the CNS. Neurotrophic factors that play an 
important role in the survival, development and function of neurons,  include brain-derived 
neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin three (NT-3) and 
neurotrophin-4/5 (NT-4/5). They belong to a class of growth factors and secreted proteins. 
BDNF was originally found in the brain, but is also found in the peripheral nervous 
system. It helps to support the survival of existing neurons and encourages the regrowth and 
the differentiation of neurons and synapses (Waterhouse and Xu, 2009). Therefore, BDNF 
has been used for treatment after CNS injuries to improve motor and sensory neuronal 
survival and outgrowth (Schmidt and Leach, 2003).  
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NT-3 is in the NGF-family of neurotrophins and binds three receptors: the receptor 
tyrosine kinase neurotrophin receptors (TrkC and TrkB) and low affinity nerve growth factor 
receptor (LNGFR). It helps to support the survival and differentiation of existing neurons, 
and encourages the growth and differentiation of new neurons and synapses. NT-3 leads to 
branching and elaboration of sensory endings (Krimm et al., 2004), promotes nerve 
regeneration and sensory improvement (Sahenk et al., 2005) and acts as a survival factor for 
adult sensory neurons (Ljungberg et al., 1999). Since the sensory pathway runs along the 
dorsal column of spinal cord and a dorsal over hemisection was used in this study, NT-3 was 
chosen for delivery into spinal cord to encourage nerve survival and outgrowth after the 
injury.  
For axonal regeneration through the lesion site after SCI, a balance between a 
permissive and favorable environment for the axons in the lesioned area is important. 
Therefore, in this study, a more permissive environment was achieved by degrading the 
inhibitory molecules CSPGs with chABC, while an improvement of regeneration ability was 
achieved by the supporting neurotrophic factor, NT-3.  
 
2.6 CONCLUSIONS 
Many researchers have shown that strategies delivering chABC alone or in 
combination with other therapeutic agents give promising results after SCI, although there 
are some limitations and difficulties. Therefore, there is a need to develop an alternative 
method to control the release of chABC temporally and spatially in vivo. In this study, we 
improved the thermal stability of chABC and developed a sustained delivery scaffold for 
topical delivery model combining 1) the chABC improved thermal stability by introducing 
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trehalose; 2) a temporal control method using lipid microtubules for long-term and 
continuous slow release; and 3) a spatial control method utilizing agarose gel to fabricate a 
scaffold for local delivery to the lesion site via implantation. 
This chapter briefly summarizes the background to design and develop strategies for 
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IMPROVEMENT OF THERMOSTABILITY OF CHONDROITINASE ABC 
ENZYMATIC ACTIVITY AND DEVELOPMENT OF LIPID MICROTUBE AND 
HYDROGEL MEDIATED DELIVERY SYSTEM  
(Partially published with R.J. McKeon and R.V. Bellamkonda, Proceedings of the National 
Academy of Sciences, 2009) 
 
Spinal cord injury (SCI) triggers cellular and molecular signal cascades which, 
amongst other things, induce growth cone inhibitors and result in regenerative failure. 
Chondroitin sulfate proteoglycans (CSPGs) are upregulated and accumulate around lesion 
sites after SCI and are major inhibitors of axonal regeneration. To overcome the inhibitory 
effect of CSPGs, modification or digestion of CSPGs has been explored. It has been reported 
that chondroitinase ABC (chABC) can digest glycosaminoglycan chains on CSPGs and 
enhance regeneration when delivered into lesion sites (Bradbury et al., 2002). However, 
chABC has a crucial limitation; it is thermally sensitive and at body temperature, 37ºC, its 
enzymatic activity is significantly attenuated within 72 hours (Tester et al., 2007). This 
necessitates the use of multiple or continuous infusions with a pump to maintain enzymatic 
functionality for periods as long as two weeks. However, maintaining these infusion systems 
is invasive and clinically problematic. Here, to overcome the current limitations, we report: 1) 
improvement of the thermal stability of chABC, and 2) development of a minimally invasive 
strategy for delivery of chABC in vivo over a period of 2 weeks or longer. By adding a 
protein stabilizer, trehalose, the thermostability of chABC was improved and chABC 
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maintained its enzymatic activity for 4 weeks. Enzymatic activity and conformational change 
were assayed by functional and structural tests such as dimethylmethylene blue staining of 
digested CSPGs, sodium dodecyl sulfate-polyacrylamide gel electrophoresis and circular 
dichroism. A scaffold consisting of lipid microtubules and agarose gel was used for sustained 
and spatially controlled release of thermally stabilized chABC in vitro. chABC released from 
the gel-microtubule scaffold showed enzymatic activity for 2 weeks. These results have 
important implications for strategies that aim to digest CSPGs as a means of reducing growth 
cone inhibition after SCI.  
 
3.1 INTRODUCTION 
Physical damage to the adult central nervous system (CNS) often leads to permanent 
functional loss due to the inability of mature axons to regenerate. A major impediment to 
regeneration is the formation of astro-glial scar tissue at the lesion site along with a number 
of myelin associated inhibitory moieties. After injury to the CNS, an inflammation process is 
triggered that includes a cascade of cellular and molecular responses occurs and a glial scar is 
formed around the lesioned tissue (Fawcett and Asher, 1999). Macrophages, microglia, 
oligodendrocyte precursors, meningeal cells and astrocytes migrate into the lesion site and 
produce inhibitory molecules, such as myelin-associated glycoprotein (MAG), CSPGs, free 
radicals, nitric oxide, etc. The final „product‟ is a tightly interwoven glial scar formed around 
the lesioned site composed primarily of CSPGs and reactive astrocytes.  
chABC has been shown to promote axonal growth and functional recovery in a 
number of models including spinal cord injury (Bradbury et al., 2002) and monocular 
deprivation (Pizzorusso et al., 2006). It promotes axonal sprouting in both intact and injured 
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spinal cords (Barritt et al., 2006), perhaps via its action on perineural nets. Currently, chABC 
is typically delivered via intrathecal injection, with infusion frequency varying from every 
other day to every other week, and for time periods ranging from 2 weeks up to 6 weeks 
(Chau et al., 2004; Caggiano et al., 2005; Houle et al., 2006; Huang et al., 2006). Some 
groups inject chABC in combination with other therapeutic agents (Tropea et al., 2003) or in 
combination with cell transplantation, such as cells from E14 fetal spinal cords (Kim et al., 
2006) or autologous peripheral nerve grafts (Houle et al., 2006), to obtain a synergistic effect. 
However, there are several limitations to using chABC in vivo. ChABC is thermally 
sensitive at body temperature, and loses 50% of its enzymatic activity after 1 hour of 
incubation at 37 ºC (by Morgan-Elson reaction; Seikagaku, Japan). Most of its enzymatic 
function is lost within 3-5 days (Tester et al., 2007). Generally, CSPGs are upregulated and 
accumulate in the lesion site for at least 2 weeks after the primary injury. Therefore for 
chABC to remove CSPGs, it would need to be delivered for at least two weeks intrathecally 
through pumps to provide a „fresh‟ supply of enzyme. Another limitation is that the diffusion 
of chABC into deep regions of the cord is limited when delivered intrathecally. Because of 
this delivery method the drug flows through intrathecal space and washes away quickly, 
necessitating high concentrations (from 2U/ml to 1000U/ml) compensate. Therefore, there is 
a compelling need to control chABC delivery both spatially and temporally. 
To overcome these limitations, trehalose was introduced as a stabilizer to retain the 
enzymatic functionality of chABC. Trehalose is a superior stabilizer among sugars or polyols 
and trehalose could give a longer lifetime to chABC. The concentration of trehalose was 
decided after in vitro experiments with various concentrations of trehalose. Second, to 
develop a sustained and local delivery system for providing bioactive agents, an agarose 
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hydrogel and lipid microtube was used. With the agarose hydrogel and lipid microtube 
mediated delivery system, the release of the drug can be temporally and spatially controlled 
by the combination of the concentration or type of agarose gel and the length of the lipid 
microtube (Meilander et al., 2001). Agarose gel was used to construct an implantable 
delivery carrier in vivo embedded with either lipid microtubes (Jain et al., 2006) or polymer 
nanoparticles (Chvatal et al., 2008; Kim et al., 2009). This is referred to as the „hydrogel-
microtube delivery system‟. Using both trehalose and the hydrogel-microtube delivery 
system, a sustained and local release of chABC and neurotrophine three (NT-3) was achieved.  
In this study, we improved the thermal stability of chABC and developed agarose gel 
scaffolds for spatio-temporal controlled delivery. The in vitro experiments performed 
determined whether trehalose can be used as a protein stabilizer to improve the thermal 
stability of chABC, and ultimately increase the lifetime of enzymatic activity at body 
temperature. In addition, lipid microtubes and an agarose hydrogel were introduced to a 
develop delivery scaffold and subsequently examined as a drug delivery system for spatio-
temporally controlled release in vitro. Last, we showed an alternative approach that will 
allow us to apply chABC as a therapeutic agent in vivo, as described later in chapter 4 and 5. 
3.2 MATERIALS AND METHODS 
3.2.1 ENZYMATIC ACTIVITY ASSAY WITH SDS-PAGE 
Because of its exceptional ability to stabilize and maintain the enzymatic activity of a 
number of proteins, trehalose was used to stabilize chABC at body temperature (37 ºC) 
(Kaushik and Bhat, 2003). To determine the proper concentration of trehalose for stabilizing 
the enzymatic function of chABC, various concentrations of trehalose, from 20 mM to 1 M, 
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were tested for their ability to digest the GAG chains of a specific CSPG, decorin, which 
consists of a core protein and a CS-GAG chain. Various concentrations of trehalose (20, 50, 
100, 250, 500 mM and 1 M) were prepared in 1X phosphate buffered saline (PBS). chABC 
(2U/0.5ml; 250ng) was mixed with these trehalose concentrations and each mixture was 
incubated for 1, 2, 3 or 4 weeks in a 37 ºC water bath. After co-incubating for different time 
durations of trehalose and chABC at 37 ºC, 10 µl of decorin (5 µg) was added, incubated at 
37 ºC for 4 additional hours and the resultant products were analyzed with sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Penicillinase (P‟ase; 250 ng) was 
used as a control enzyme. 
When intact, decorin appears as a large molecular weight smear on an SDS-PAGE gel. 
A tighter and lower molecular weight decorin band after incubation with chABC would 
indicate preservation of chABC enzymatic activity. chABC without trehalose was used as a 
negative control and was incubated at 37 ºC for the same incubation durations, mixed with 
decorin, and incubated at 37 ºC for an additional 4 hours. After incubating, the mixtures were 
diluted 1:1 with Tris-SDS sample buffer containing 5% β-mercaptoethanol and were further 
incubated for 4 minutes at 95 ºC to denature the protein. The gel electrode assembly was 
placed in an electrophoresis chamber (BIORAD) and the chamber was filled with Tris 
running buffer. 20 µl of the prepared samples was loaded into each lane of SDS gradient gel 
(4% - 15%; BIORAD) and run at 200 volts for 1 hour.  
Silver staining was conducted to visualize separated proteins. Because the enzymatic 
thermostability of chABC depends on lot and time (Tester et al., 2007), all experiments in 




3.2.2 SILVER STAINING PROCEDURE 
After running on SDS-PAGE, the gel was fixed in a solution containing methanol, 
acetic acid, and water in a 45:5:50 ratio for 90 min and washed with water for 20 min twice. 
The gel was washed with 0.02 sodium thiosulfate (Na2S2O3·5H2O) for 3 min and with 
water for 30 sec twice, then washed with 0.1 % silver nitrate for 30 min and with water for 
30 sec. A developing solution containing 2.5 % sodium carbonate/ 0.02% formaldehyde was 
added. The gel was developed for 2-4 min and protein bands generally appeared within 30 
sec. The developing solution was removed before overdevelopment and a solution containing 
1 % acetic acid was added to quench the reaction. After rinsing with water, the gel was 
imaged on the BIORAD ChemiDoc XRS HQ in the epi-white mode.  
 
3.2.3 ENZYMATIC ACTIVITY ASSAY WITH DMMB 
To further characterize stability of chABC, a dimethylmethylene blue (DMMB) assay 
was used to quantify CS-GAGs that remained after digestion of decorin with chABC. Diluted 
chABC (40mU) in 1X PBS (200µl) was mixed with 1 M of trehalose and incubated at 37 ºC 
to subject it to thermal stress. 10 µl of incubated chABC solution was sampled for analysis 
on day 1, 3, 7 and 14. The sampled chABC/trehalose was then mixed with 10µg of decorin 
and incubated at 37 ºC for 10 minutes. Next, the DMMB reagent was added and absorbance 
was measured on a Microplate Reader (BIO-TEK Instruments, Inc.). The same concentration 
of chABC/trehalose without added decorin was measured as the background on the same 
plate and the measured background absorbance was subtracted from absorbance of the other 
samples. chABC in 1X PBS without trehalose was prepared to determine the degree to which 
the enzymatic activity of chABC is improved by adding trehalose. The absorbance of decorin 
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digested by fresh chABC was considered to represent 100% of enzymatic activity. The 
percentage of sample absorbance relative to this standard was calculated and a deactivation 
curve was plotted. The absorbance of trehalose in 1X PBS at the same concentration as above 
was measured to make sure that trehalose does not interfere DMMB results. 
 
3.2.4 FABRICATION OF LIPID MICROTUBES 
Hollow and open-ended lipid microtubes (Fig. 3.1.) were fabricated using 1,2-bis-
(triscosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC8,9PC, Avanti Polar Lipids, 
Alabaster, AL) as previously described (Meilander et al., 2001; Meilander et al., 2003). 
Briefly, the lipid was dissolved in 70% ethanol at a concentration of 1 mg/ml. The solution 
was slowly cooled from 55 ºC to 21 ºC, heated to 33 ºC and cooled again to 20 ºC by a 
programmed water bath (Thermo NESLAB, Portsmouth, NH) for 48 hours. During this 
cooling procedure, the microtubes self-assembled into hollow structures (Spargo et al., 1995; 
Meilander et al., 2001). The average length of microtube can be controlled by modifying the 
cooling process (Lando et al., 1990; Thomas et al., 1995). After 2 weeks of incubation at 
room temperature, 50 mM (18.9 mg/ml) of trehalose was added to the microtube solution, 
mixed gently and incubated overnight to support the stability of the lipid microtube structure. 
The microtube solution was centrifuged for 5 min at 3000 rpm, dried overnight in a 
biological hood for complete lyophilization. Microtubes were loaded with chABC, NT-3 or 
P‟ase in buffer, 1 M trehalose in 1X PBS, and incubated overnight at 4 ºC to allow for full 
rehydration. Microtubes were transferred to a new tube and extra buffer, 1 X PBS, was added 




Figure 3.1. Micrograph of lipid microtubes formed from DC8,9PC lipid in 
bright field microscopy, scale bar is 50 µm. Figure from Meilander et al., 
2001.  
 
3.2.5 PREPARATION OF AGENT-LOADED LIPID MICROTUBES 
The loading concentration of the drug was calculated based on the loading efficiency. 
The loading efficiency was defined as the ratio of the entire internal volume of the 
microtubes to the volume of the drug solution added to lyophilized microtubes (Meilander et 
al., 2001). Figure 3.2 shows a histogram of the lengths of microtubes used in this study. The 
average length was about 37 µm (0.5 µm of inner diameter) and the total number of 
microtubes from 1 mg of lipid was approximately 1 × 10
8
. Therefore, the total inside volume 
of microtubes yielded from 1 mg of lipid was 0.75 µl. To increase the loading efficiency, we 
tried to increase the internal volume of lipid microtubes by using more lipid solution, 
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increasing the surface area of lyophilized microtubes for more efficient rehydrating with the 
solution of interest, and decreasing the loaded volume of solution of interest.  
 
Figure 3.2. Histogram of microtube length distribution. The average length 
is about 37 µm, total number of microtubes from 1 mg of lipid is 
approximately 1 × 10
8
 and total inside volume of microtubes from 1 mg of 
lipid is 0.75 µl.  
 
 
3.2.6 ENZYAMTIC ACTIVITY ASSAY OF POST-RELEASED CHONDROTINASE 
ABC FROM LIPID MICROTUBES/HYDROGEL-MICROTUBE DELIVERY 
SCAFFOLD 
SDS-PAGE was used to examine any potential adverse effects of the lipid microtubes 
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assay was used to characterize the release profile of chABC from microtubes. After preparing 
microtubes loaded with chABC (~20 mU) and 1 M trehalose, the microtubes were co-
incubated with decorin (5 µg/200 µl). After 4 hours at 37 ºC, the co-incubated samples were 
centrifuged and the supernatant was analyzed by SDS-PAGE as described in the section 3.2.1.  
The enzymatic activity of released chABC from the hydrogel-microtube delivery 
system was characterized via DMMB assay. In order to physically maintain 
chABC/trehalose/microtubes in place in vivo, SeaPlaque® agarose (Cambrex), an agarose 
hydrogel, was dissolved in 1X PBS at a concentration of 1.2% (w/v) (Jain et al., 2006; Dodla 
and Bellamkonda, 2008). After it was cooled below 37 ºC, the gel was mixed with an equal 
volume of microtubes loaded with chABC/ 1M trehalose, placed in a 96-well plate, and 
gelled at 4 ºC. The final working concentration of the gel was 0.6% (w/v).  After the mixture 
gelled, 1X PBS was added above the mixture and incubated in a 37 ºC incubator for up to 2 
weeks. During this incubation, the supernatant was collected and replaced with fresh 1X PBS 
every other day. The collected supernatant was mixed with decorin, incubated at 37 ºC and 
analyzed with DMMB assay as described in the section 3.2.3. The same measurement was 
conducted with microtubes loaded with P‟ase (50 ng; same amount as chABC) and trehalose 
as an enzyme control.   
 
3.2.7 CHABC RELEASE PROFILES FROM LIPID MICROTUBES 
The delivered amount can be determined by calculating the loading efficiency, which 
is the ratio between the loaded volume of therapeutic agent and the entire internal volume of 
the microtubes. After the release profile of the agent loaded microtubes is measured in vitro, 
the daily delivered amount of agent in vivo can be predicted. Currently, there is no 
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commercially available kit for quantifying chABC levels or antibody to chABC, therefore, 
the release profile of chABC was determined via SDS-PAGE and silver staining. The 
samples of chABC released from the hydrogel-microtube mixture were prepared as described 
in section 3.2.6, and the amount of chABC was determined via SDS-PAGE as described in 
section 3.2.1 and silver staining as described in the section 3.2.2. Various different amounts 
of chABC were prepared as a standard and run on SDS-PAGE at the same time with the 
collected samples. Intensity measurements of the collected samples and chABC standards 
were detected using a Microplate Reader (BIO-TEK Instruments, Inc.). The amount of the 
released chABC was determined by the standard curve and the release profile was obtained. 
 
3.2.8 NT-3 RELEASE PROFILES FROM LIPID MICROTUBES 
NT-3 was loaded into lipid microtubes and the release profile of NT-3 was 
determined by using methods similar to those previously published (Jain et al., 2006). An 
NT-3 Sandwich ELISA Kit (Chemicon) was used to quantify the NT-3 release profile. NT-3 
(PeproTech Inc.) containing microtubes were mixed with SeaPlaque® agarose gel, placed in 
a 96-well plate, and cooled for gelation (30 ng per plate). The final working concentration of 
the gel was 0.6 % (w/v). During incubation in a 37 ºC incubator for 2 weeks, the supernatant 
was collected and replaced with fresh PBS every other day after sampling at day 1 and stored 
at -80 ºC.  The retrieved supernatants were pooled for the NT-3 ELISA and absorbance 
measurements of the samples were taken at 450 nm using a Microplate Reader (BIO-TEK 
Instruments, Inc.). The amount of the NT-3 was determined by the standard curve and the 




3.2.9 ANALYSIS OF TEMPERATURE DEPENDENT CONFORMATION OF CHABC  
To investigate the potential of conformational changes contributing to the thermal 
destabilization of chABC, we conducted circular dichroism (CD) studies with and without 
trehalose stabilization. chABC was dissolved into 50 mM sodium phosphate (pH 7.4) and 
placed in 10 mm light path length quartz cells. Scans collected measurements from between 
195 and 300 nm with a 1nm bandwidth. For the denaturation curve, scans collected 
measurements from between 5 and 85 ºC at a wavelength of 222 nm with a scan rate of 2.5 
ºC/min. Four scans were averaged for each running condition. The transient temperatures 
between fresh chABC in buffer and chABC in trehalose solution were compared.  
 
3.3 RESULTS 
3.3.1 FUNCTIONAL STABILITY OF CHABC AT BODY TEMPERATURE (37 ºC) 
WITHOUT THERMAL STABILIZATION 
We investigated the enzymatic activity of unstabilized versus trehalose-stabilized 
chABC by evaluating its ability to digest the CSPG decorin followed by SDS-PAGE. 
Decorin, our model CSPG, has a simple molecular structure consisting of one chondroitin or 
dermatan sulfate GAG chain on its core protein. Intact decorin migrates as a larger molecular 
weight broad smear on an SDS-PAGE gel (Fig. 3.3, Lane 3). A tighter and lower molecular 
weight decorin band after digestion by chABC indicates preservation of chABC activity. 
When the CS-GAG chain of decorin was digested by chABC, the core protein migrates at 
~40-45 kDa (Fig. 3.3, Lane 1), and chABC alone migrates between 97 kDa and 116 kDa (Fig. 
3.3, Lane 4). chABC pre-incubated for 24 hours at 37 ºC retained its ability to degrade 
decorin (Fig. 3.3, Lane 2), but chABC lost the ability to completely degrade decorin GAG 
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chains after 1 week of pre-incubation at 37 º (Fig. 3.3, Lane 5). In contrast, following 
incubation with 1 M trehalose at 37 ºC for one week, chABC retained its ability to degrade 
decorin (Fig. 3.3, Lane 6). 
  
 
                                              1             2              3             4           5             6 
Figure 3.3. SDS-PAGE assay for chABC enzymatic activity after 1 
day pre-incubation and 1 week of pre-incubation at 37 ºC with and 
without trehalose. Lane 1: fresh chABC + decorin, Lane 2: 1 day pre-
incubated chABC + decorin, Lane 3: intact decorin, Lane 4: chABC, 
Lane 5: 1 week pre-incubated chABC + decorin, and Lane 6: 1 week 
pre-incubated chABC with trehalose + decorin. Thermostability of 
chABC was enhanced with trehalose and trehalose-chABC still 




3.3.2 TREHALOSE SIGNIFICANTLY ENHANCES THERMOSTABILITY OF CHABC 
ENZYMATIC ACTIVITY 
To improve the thermal stability of chABC, trehalose was introduced as a protein 
stabilizer. To determine the proper concentration of trehalose, different concentrations of 
trehalose, from 20 mM to 1 M, were evaluated for their ability to preserve chABC enzymatic 
activity. Trehalose concentrations above 500 mM successfully preserve chABC enzyme 
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Figure 3.4. chABC enzymatic activity assay with different 
concentrations of trehalose by SDS-PAGE. Each lane represents 1) 20 
mM, 2) 50 mM, 3) 100 mM, 4) 250 mM, 5) 500 mM and 6) 1M of 
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Figure 3.5. chABC enzymatic activity test after 4 weeks of pre-
incubation with and without trehalose at 37 ºC by SDS-PAGE. Lane 1: 
4 weeks pre-incubated chABC with trehalose + decorin, Lane 2: 4 
weeks pre-incubated chABC + decorin, Lane 3: fresh chABC + 
decorin, Lane 4: decorin, Lane 5: fresh chABC + decorin, Lane 6: 
fresh P‟ase + decorin, and Lane 7: fresh P‟ase (out of molecular 
weight range from gel; ~28 kDa). The trehalose-thermostabilized 
chABC still retained its activity to degrade CS-GAG of decorin after 4 
weeks of pre-incubation at body temperature and P‟ase had no effect 





To investigate whether trehalose can preserve chABC activity at 37 ºC for longer 
periods, 1M trehalose-chABC solutions were pre-incubated for 4 weeks at 37 ºC, and then 
added to decorin for digestion. In figure 3.5, Lane 1 demonstrates that after 4 weeks of pre-
incubation with 1 M trehalose, chABC digested decorin, and confirms the ability of trehalose 
to preserve chABC activity at 37 ºC. In comparison, after 4 weeks of incubation in PBS at 37 
ºC without trehalose, chABC lost its enzymatic activity (Fig. 3.5, Lane 2). Decorin incubated 
with fresh chABC (Fig. 3.5, Lane 3) and intact decorin (incubated for 4 hours at 37 ºC; Fig. 
3.5, Lane 4) were run as controls at the same time. P‟ase was used as a control enzyme, and 
when decorin was incubated with P‟ase at 37 ºC (Fig. 3.5, Lane 6), no decorin digestion was 
observed as expected. P‟ase was not shown (P‟ase alone; Fig. 3.5, Lane 7) because molecular 
weight of P‟ase (28 kDa) is out of range of this molecular standard weight. 
 
3.3.3 TEMPERATURE STABILIZATION OF CHABC BY TREHALOSE IS DUE TO 
CONFORMATIONAL STABILITY  
Deactivation profiles of chABC enzymatic activity with and without trehalose over 
time were evaluated with by the DMMB assay (Fig 3.6).  At every time point except day 1, 
there was a statistically significant difference between control and trehalose treated samples. 
The enzymatic activity of chABC was maintained up to day 15 with trehalose. In comparison 
however, without trehalose, chABC quickly lost its enzymatic activity after day 3 and was 
completely inactive by day 5. Based on this deactivation study, a kinetic deactivation 
constant kd was evaluated by assuming a two-state transition between native state (N), to 
unfolded state (D):  
N  D 
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dN/dt = − kbN;      N= N0exp(− kbt) 
where N0 represents initial N and the first-order kinetics was adapted (the dotted line in 





=0.98]. The slope of the decline in chABC activity when it is thermostabilized by trehalose 






To investigate whether increased thermal stability of chABC in the presence of 
trehalose is due to conformational stabilization of the enzyme, conformational changes in 
chABC as a function of temperature with and without trehalose were quantified by CD (Fig. 
3.7). Ellipticity change measured by CD is directly proportional to the change in 
concentration of native and unfolded forms; therefore CD has been applied to protein folding 
study. The thermodynamics of protein conformational stability can be described by following 
equations (Greenfield et al., 1999): 
K = α / (1− α)   (1) 
∆G = nRTlnK;  ∆G = ∆H − T∆S  (2) 
θobs = (a1-a2) α + a2  (3) 
where K is the equilibrium constant of folding, α is the friction folded, ∆G is the free energy 
of folding, R is the gas constant, T is temperature (Kelvin), ∆H is the enthalpy of folding and 
∆S is the entropy of folding. θobs represents the observed ellipticity, a1 is fully folded 
(maximum) θobs and a2 is fully native (minimum) θobs. Based on these equations, ∆H and the 




Figure 3.6. Kinetic analysis of chABC deactivation by DMMB assay. The 
X axis represents days and the Y axis represents percentage of digested 
decorin. Asterisks denote a significant difference from chABC in 1X PBS 
(P < 0.05) and data represent mean ± SEM. The dotted line represents the 
calculated deactivation curve of chABC in 1x PBS. Data are mean ± SEM. 
chABC in 1X PBS (×) loses most activity within 5 days, and in contrast, 
chABC in 1 M trehalose (Δ) retains its activity to degrade decorin CS-




Initial values of ∆H, Tm, a1 and a2 were estimated, and calculated θ was fitted to the θobs by 
curve fitting routine. The spectrum was measured at 222 nm and from 20 °C to 90 °C at the 
rate of 2.5 °C/min and 1 min of delay. The Tm, ∆Hm and ∆Sm of chABC in 1 M trehalose 
solution were 64.2 °C, 171 kJ∙mol
-1




 respectively, versus the Tm, ∆Hm and 
∆Sm of chABC dissolved in sodium phosphate buffer were 56.2 °C, 176 kJ∙mol
-1







. Therefore, the increment in the midpoint of transition, ΔTm, between the two 
conditions is 8 °C, indicating that chABC‟s conformation is thermally more stable in the 






Figure 3.7. The normalized thermal denaturation curves (fraction unfolded) 
of chABC in pH 7.4 were measured by the changes of the absorbance at 
222nm. The dashed line represents chABC in 50 mM sodium phosphate 
buffer and the solid line represents chABC in 1M trehalose solution. Tm of 
chABC in 1 M trehalose solution was 64.2 °C and the Tm of chABC 
dissolved in buffer solution was 56.2 °C. Therefore, the increment in the 
midpoint of transition, ΔTm, between the two conditions is 8 °C and can be 



















3.3.4 LIPID MICROTUBE ENCAPSULATED CHABC IS BIOLOGICALLY ACTIVE 
FOR 2 WEEKS 
To verify that self-assembled, hollow lipid microtubes (0.5 microns x 40 microns in 
dimensions) can be loaded with chABC without compromising its enzymatic activity, 
chABC released from fresh microtubes (without pre-incubation at 37 ºC) was tested with 
SDS-PAGE (Fig. 3.8B) for its ability to digest decorin. As indicated by the digested decorin 
band, microtube loading does not negatively impact chABC activity. 
After confirming that lipid microtubes can be used for chABC delivery, post-release 
activity of chABC or P‟ase from microtubes was plotted (Fig. 3.8A) as a function of time, 
and their relative enzymatic activity was measured by DMMB assay (Melrose and Ghosh, 
1988; de Jong et al., 1989). 100% of digested decorin on the Y-axis represents 1X PBS with 
no decorin. This release profile showed that, when combined with trehalose, chABC released 
from microtubes retained its enzymatic activity up to 15 days in vitro. As expected, the 
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                  (B)                                       
Figure 3.8. Enzymatic activity of post-released chABC from lipid microtubes. 
(A) Quantification of the amount of CS-GAGs that remained after digestion of 
decorin with the released enzymes by DMMB assay. chABC (Δ) and P‟ase (×) 
with trehalose/microtubes. The Y-axis represents percentage of digested 
decorin and the X-axis represents time. All data points are significantly 
different (P < 0.05; mean ± SEM). (B) SDS-PAGE assay of chABC released 







3.3.5. RELEASE PROFILE OF MICROTUBE ENCAPSULATED NT-3 CONFIRMS A 
SUSTAINED DELIVERY FOR 2 WEEK  
To characterize the release profile of NT-3, NT-3 released from microtubes was 
tested with NT-3 sandwich ELISA kit to measure released amount (Fig. 3.9).   
 
 




The purpose of this study was to develop an approach that allows the application of 
chABC as a therapeutic agent in vivo. chABC is one of the more promising therapeutic 
interventions for SCI, however, the thermal instability of chABC compromises its potential 
for in vivo application (Tester et al., 2007). In this study, we demonstrate that the enzymatic 
activity of chABC could be maintained at body temperature over time and that 


























weeks remains enzymatically active in vitro. In this chapter, it is shown that this hydrogel-
microtube delivery scaffold has a potential to provide an alternative delivery method to 
chronically implanted, invasive pumps, which is minimally invasive and effectively delivers 
chABC in vivo. 
After 24 hour incubation at 37 ºC, the enzymatic activity of chABC, which is used in 
this study, was still preserved. However after 1 week of incubation at 37 ºC, a broaden 
decorin band appeared (Fig. 3.3, Lane 5), indicating that enzymatic activity was weakened 
leading to incomplete digestion of CS-GAGs on decorin even after sufficient reaction time. 
At body temperature chABC quickly loses most of its enzymatic activity within 5 days (the 
DMMB assay; Fig. 3.6; ×-dashed line) and the retained enzymatic activity is not enough to 
completely digest CS-GAG chains, though partial digestion is still possible (seen as a 
broaden band in SDS-PAGE assay; Fig. 3.3). chABC typically lost most of its enzymatic 
function within one week at body temperature, however the rate of enzymatic activity loss 
and the amount of enzymatic activity retained depend on several factors. The SDS-PAGE 
assay showed different retained activities of chABC from different lots. Other studies also 
showed that enzymatic thermostability of chABC depends on lot and time (Tester et al., 
2007). Large differences exist between lots, since function can be lost anywhere from 1 day 
to 2 weeks, so all experiments in this study were performed with chABC from the same lot. 
Biodegradable polymer nanoparticles also could be considered as a carrier for 
sustained delivery of chABC (Cohen et al., 1991; Genta et al., 2001; Kim and Burgess, 2002; 
Singh et al., 2009). Before using the lipid microtube, poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles were examined as drug carriers for chABC in a preliminary.  The double 
emulsion method was used to make PLGA nanoparticles, and is simple, takes a relatively 
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short time and is easy to store in powder form at -80 ºC after lyophilizing comparing to the 
fabrication procedure of lipid microtubes.  After fabricating powder form of PLGA 
nanoparticle encapsulating chABC, the enzymatic activity of chABC released from the 
PLGA particles was characterized with the same assessment described in the section 3.2.1.  
However the mark band (Fig. 3.3, Lane 1) presenting core protein due to GAG chain 
digestion by chABC was not observed and a broad band of decorin, similar to the one in 
Lane 5 of figure 3.3, was seen in the gel.  chABC lost its enzymatic activity after the 
fabrication procedure of PLGA nanoparticles.  It is possible that proteins undergo physical 
denaturation and chemical degradation during fabrication. The acidification of the internal 
PLGA microenvironment and the water-in-oil-in-water (w/o/w) encapsulation procedure are 
considered major protein stresses inducing inactivation and aggregation (van de Weert et al., 
2000; Perez-Rodriguez et al., 2003; Estey et al., 2006).  During the double emulsion 
procedure, chABC is exposed to organic solvents, dichloromethane, and the pH of inside 
particles is predominantly below pH 5.8 (detection limit in this paper, Li and Schwendeman, 
2005).  
Our laboratory has previously reported the use of lipid microtubes for the slow 
delivery of a variety of proteins (Meilander et al., 2001), DNA (Meilander et al., 2003; Yu 
and Bellamkonda, 2003; Meilander-Lin et al., 2005) and neurotrophic factors (Yu and 
Bellamkonda, 2003; Jain et al., 2006) in vivo. Relative to other delivery systems such as 
polyester based PLGA nanoparticles, lipid microtubes have the advantage that there is no 
exposure to heat or organic solvents that might cause denaturation or degradation, during the 
fabrication process. As is evident from figure 3.8B, release from lipid microtubes does not 
adversely affect the enzymatic activity of chABC. In addition to that, lipid microtubes are 
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injectable either by themselves, or when embedded in thermo-reversible hydrogels as 
reported in Jain et al. (2006), Dodla et al. (2008) and Chvatal et al. (2008).  
Here, the lipid microtube-gel delivery system provides sustained delivery of 
thermostabilized chABC over a period of 2 weeks, with the microtubes enabling slow release 
while the hydrogel localizes the tubes to the lesion site. We have developed a mathematical 
model (Meilander et al., 2001), to predict the release profile of compounds with a range of 
molecular weights such as myoglobin (17.8 kDa), albumin (66.4 kDa) and thyroglobulin 
(660 kDa). These studies suggest that an initial burst release of protein from day 1 to day 3 is 
followed by a slow and continuous release, leading to a cumulative percentage of released 
agents of 80-100% by day 14.  Further, microtubes show a stable and continuous release 
profile with delivery of BDNF (Brain derived neurotrophic factor) (Jain et al., 2006), and 
NT-3 (neurotrophin-3) (Dodla and Bellamkonda, 2008).As the molecular weight of chABC 
(120 kDa) is within the protein molecular weight range previously tested, most of the chABC 
loaded into microtubes is likely released by day 14.   
In this study, we chose to stabilize chABC by adding trehalose since it is known as an 
exceptional stabilizer and widely used with proteins (Carninci et al., 1998; Kreilgaard et al., 
1998). The molecular mechanism of trehalose-mediated thermostabilization is still poorly 
understood (Hedoux et al., 2009). There are several hypotheses outlining the mechanisms of 
protein stabilization by trehalose – water replacement (Crowe et al., 1984), preferential 
hydration (Timasheff, 2002), vitrification of solutions (Green et al., 1989) and the influence 
of trehalose on the water tetrahedral hydrogen bond network (Branca et al., 1999). Previous 
works have shown that surface tension of trehalose solutions increases linearly with increase 
in trehalose concentration (Kita et al., 1994), and there is a strong correlation between 
69 
 
surface tension and increase in Tm (Kaushik and Bhat, 2003). Studies have shown that the 
dynamic fluctuation of polar side chains at the solvent-protein interface was reduced in the 
presence of trehalose (Hedoux et al., 2009). The increased surface tension or the limited 
exposure of hydrophobic groups to the water molecules leads to preferential hydration, 
resulting in the stabilization of the tertiary structure of protein (Timasheff, 2002). In this 
study, the Δ Tm of chABC (8 °C) with 1M trehalose addition is similar in range to its effects 
on other enzymes such as RNase A (5.5 °C) and lysozyme (8.4 °C) (Kaushik and Bhat, 2003), 
where increased conformational thermostabilization (increase of Tm) induces an increase in 
enzymatic activity. These enzymes also show an increase of ΔTm when concentration of 
trehalose increases, and it describes the observation that only high concentration (500 mM 
and 1 M) of trehalose preserved the enzymatic activity of chABC in this study. Therefore, 
trehalose‟s ability to thermally stabilize chABC is consistent with its effects on other 
enzymes. 
3.5 CONCLUSIONS 
In this study, improvement of thermostability of chABC enzymatic activity was 
attained by adding trehalose up to 4 weeks. We demonstrated that thermostabilized chABC 
can be slowly delivered by the lipid microtube-hydrogel delivery system and the released 
chABC retains its enzymatically activity over two weeks in vitro.  Therefore, these 
achievements of thermostabilization and development of the sustained delivery system 
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DELIVERY OF THERMOSTABILIZED CHABC BY IMPLANTING HYDROGEL-
MICROTUBE SCAFFOLDS AFTER SPINAL CORD INJURY AND EXAMINATION 
OF CELLULAR AND MOLECULAR RESPONSES: SHORT TERM STUDY  
(Partially as published with R.J. McKeon and R.V. Bellamkonda, Proceedings of the 
National Academy of Science, 2009 ) 
 
Chondroitin sulfate proteoglycans (CSPGs) are upregulated and accumulate around 
the lesion site after spinal cord injury (SCI), and are major inhibitors of regeneration. To 
overcome CSPG-mediated inhibition, modification or digestion of CSPGs with 
chondroitinase ABC (chABC) has been explored. chABC digests glycosaminoglycan (GAG) 
chains on CSPGs and enhances sprouting and regeneration when delivered to the lesion site. 
However, chABC has a crucial limitation; it is thermally unstable at body temperature (37ºC) 
and its enzymatic activity is significantly attenuated within 3 days. Therefore, multiple or 
continuous infusions with an indwelling catheter are necessary to maintain enzymatic 
functionality for periods of 2 weeks or longer and such devices are invasive and clinically 
problematic. To overcome these limitations, we enhanced the thermal stability of chABC by 
adding a protein stabilizer, trehalose, and demonstrated that chABC maintained its enzymatic 
activity for 4 weeks at 37 ºC in vitro. Also, we developed a delivery scaffold for chABC in 
vivo application in the temporally and spatially controlled manner. 
In this chapter, a dorsal over hemisection injury was made at thoracic vertebrae T10 
in adult rats, and thermally stabilized chABC was delivered to the lesion site by a minimally 
75 
 
invasive hydrogel-microtube scaffold carrying chABC-loaded lipid microtubules at the lesion 
site immediately following injury. To determine the effectiveness of topical delivery of 
thermostabilized chABC, animal groups treated with single injection or hydrogel scaffold 
implantation of chABC, chABC/trehalose and P‟ase were included as controls. Two weeks 
after surgery, the enzymatic functionality of released chABC in vivo was examined by CS-56, 
WFA and 3B3 immunostaining.   
The results demonstrated that thermally stabilized chABC was successfully delivered 
slowly and locally without a catheter/mini-pump and the released chABC effectively 
digested CSPGs in vivo and significant differences of CSPG digestion were observed in 3B3-
IR and CS-56-IR between groups. We suggest that chABC could be combined with other 
therapies or agents, such as neurotrophic factors to treat SCI. 
 
4.1 INTRODUCTION 
After injury, a series of cellular and molecular events occur, and results in the 
formation of astro-glial scar tissue consisting of interwoven reactive astrocytes and 
chondroitin sulfate proteoglycan (CSPGs). The CSPG-astroglial scar provides a non-
permissive environment for axon regeneration. Studies have shown that CSPGs are 
upregulated after injury in the CNS and neurite regrowth is inhibited by CSPGs (McKeon et 
al., 1995; Stichel et al., 1995; Lemons et al., 1999; Jones et al., 2002). It has been shown that 
growth cone stall or change growth orientation at the CSPG-rich region in vitro and in vivo. 
Therefore, it is important to remove or attenuate the inhibitory nature of CSPGs by 
modifying CSPGs and to encourage axons to regrow through the inhibitory regions around 
the lesion site. Therefore, chABC has been used to treat SCI, based on the concept that 
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removing or attenuating inhibitory activity of CSPGs could promote axonal regeneration. 
After promising results for axonal outgrowth were reported in vitro (Snow and Letourneau, 
1992; Zuo et al., 1998) and in vivo (Yick et al., 2000; Moon et al., 2001; Bradbury et al., 
2002; Yick et al., 2003; Chau et al., 2004; Caggiano et al., 2005; Barritt et al., 2006; Houle et 
al., 2006), it has received a lot of attention as a potential therapy for spinal cord injury.  
chABC shows the best enzymatic activity at 37 ºC and the optimum pH is near 8.0. 
At physiological conditions, body temperature 37 ºC and 7.4 pH, chABC should be suited for 
in vivo usage. However, as described in the previous chapters, there are crucial limitations 
when delivering chABC for SCI treatment, such as thermal stability of chABC and 
difficulties with spatio-temporal control. In general, CSPGs are upregulated and deposited 
around the lesion site for at least 2 weeks after the initial injury, and the CSPG-rich matrix 
surrounding the lesion site persists for up to 8 weeks following injury (Jones et al., 2003). 
Therefore, for chABC to degrade CSPG associated glycosaminoglycans (GAGs), a “fresh” 
supply would need to be delivered intrathecally for at least two weeks. Currently this is 
achieved via intrathecal injection, with the infusion frequency varying from days to weeks, 
and for time periods ranging from 2 to 6 weeks to compensate the rapid loss of enzymatic 
activity of chABC. A single administration of chABC containing gelfoam on lesion site of 
T11 hemisection promotes Clarke‟s nucleus neurons to regrow beyond the injury (Yick et al., 
2000; Yick et al., 2003). Multiple or continuous infusions were also administrated, using an 
osmotic mini-pump (Chau et al., 2004; Houle et al., 2006; Huang et al., 2006) and catheters 
with externalized cannulas (Moon et al., 2001; Bradbury et al., 2002; Caggiano et al., 2005; 
Barritt et al., 2006).   
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Diffusion of chABC into deep regions of the cord, however, is limited when delivered 
intrathecally due to overflow into the intrathecal space, thereby diluting the enzyme rapidly 
and necessitating concentrated infusions (from 2 U/ml to 1000 U/ml) to compensate. With 
the exception of catheters with externalized cnnulas, the efficiency of CSPG digestion is 
dependent on the enzyme‟s stability at body temperature.  Therefore, there is a compelling 
need to develop clinically viable methods for the spatially and temporally controlled delivery 
of „fresh‟ chABC, preferably in a manner confining it to the lesion site. We demonstrated an 
alternative method using trehalose-thermostabilized chABC and a hydrogel and lipid 
microtube based minimally invasive system to deliver chABC in a temporally and spatially 
controlled manner in vivo in chapter 3.  
Therefore, the study in chapter 4 was designed to investigate chABC‟s activity in vivo 
at the lesion site after SCI when delivered via our lipid microtube-hydrogel system and 
compare the CSPG digestion efficiency to a single injection of chABC. In this short term 
(two week) animal study, we locally delivered chABC to the lesion site by a topical delivery 
model and the dorsal over-hemisection injury was used. Thermostabilization of chABC and 
development of sustained delivery scaffold were achieved previously in the chapter 3. Two 
weeks after surgery, the animals were sacrificed, and the functionality of chABC released 
from the gel scaffold was examined. CS-56 and 3B3 immunostaining were used to examine 
the level of CSPGs and CSPG digestion by chABC‟s activity, and WFA was used to 






4.2 MATERIALS AND METHODS 
4.2.1 FABRICATION OF MICROTUBE-HYDROGEL SCAFFOLDS 
The fabrication procedure of the lipid microtube was previously published (Meilander 
et al., 2001; Meilander et al., 2003) and described in the Chapter 3, section 3.2.4. The 
hydrogel-microtube delivery scaffolds were fabricated by loading chABC/ 1M trehalose 
solution into the microtubes, and mixed with an equal amount of 2% (w/v) SeaPrep® agarose 
gel (Cambrex) in 1X PBS for 1% of final gel concentration. Before mixing SeaPrep agarose 
gel with the microtubes, the gel solution was filtered for sterilization and cooled to below 37 
ºC to avoid deactivation of chABC or P‟ase due to high temperature. After complete gelation 
at 4 ºC, each gel scaffold contained 10mU of chABC prior to being implanted in SCI animals, 
as described below, section 4.2.2. 
 
4.2.2 TOPICAL DELIVERY OF HYDROGEL-MICROTUBE SCAFFOLDS IN A 
DORSAL OVER HEMISECTION INJURY MODEL 
Adult male Spraque-Dawley rats (Charles River Laboratory) weighing between 
235~260 g were anesthetized with 2% of isoflurane and maintained during surgery with 0.5% 
of isoflurane. The surgical area was shaved and the skin and muscles were opened to expose 
the thoracic vertebrae T9-T11. A single laminectomy was performed on T10 to expose the 
spinal cord by removing the bone with a micro-rongeur and the dura mater was excised. 
Using micro-scissors marked at 1.5 mm depth from the tip, a controlled dorsal hemisection 
injury (2 mm of width x 1.5 mm of depth) was made by cutting the dorsal columns at T10. 
Sustained topical delivery of thermostabilized chABC (MTC; n=8) was achieved using 
methods previously published (Chvatal et al., 2008).  Briefly, the SeaPrep agarose hydrogel 
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embedded with lipid microtubes loaded with either chABC/1M trehalose or chABC alone 
was placed on top of the lesion site as shown schematically in figure 4.1. To stabilize the 
hydrogel embedded microtubes in place, a stiffer 0.7% of SeaKem agarose hydrogel solution 
was added on top. This denser gel was quickly gelled in situ by a stream of cooled air (Fig. 
4.2) as described in a previous study (Jain et al., 2006). After ensuring complete gelation, the 
muscles were sutured together and the skin was closed with wound clips. Figure 4.3 
demonstrates the topical delivery model applied into the spinal cord lesion site.   
Table 1 describes experimental and control groups. As controls, 10 mU of chABC in 
5 µL of 1X PBS (SC; n=6) or 1 M trehalose/1X PBS (STC; n=6) was injected as „single 
injection‟ conditions that have local, but not sustained delivery. 100 ng of P‟ase (Sigma) was 
delivered by single injection (STP; n=6) or hydrogel-microtube scaffold (MTP; n=6) with 
1M trehalose as a negative enzymatic delivery control for chABC specificity. Sham (Sham; 
n=4) and trehalose loaded hydrogel scaffold conditions (MT; n=6) were also conducted. To 
avoid differences in the tissue reaction caused by absence of SeaKem agarose gel, after a 
single injection of agents, a pre-made SeaKem block was placed on top of the lesion site. 
After two weeks, the animals were anesthetized with a ketamine-xylazine-acepromazine 





Figure 4.1. Schematic of spinal cord injury model and delivery of enzyme to 
lesion site. The 1 % SeaPrep agarose gel-microtube-scaffold is implanted on 
top of the lesion and covered with stiffer 0.7% SeaKem agarose gel to keep 
the scaffold in place.   
 
 
Figure 4.2. Schematic of gel cooling system. Tubing runs from the nitrogen 
gas tank to a Styrofoam box containing 100% ethanol and dry ice, and runs 
through an aluminum rod inside a tube containing dry ice to keep the 
nitrogen gas cool. The cooled nitrogen gas was applied over the stiffer 
agarose gel solution for in situ gelation, which covers the top of the gel-
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Figure 4.3. This figure demonstrates the topical delivery model applied into 
the spinal cord lesion site.  A) Exposed intact spinal cord at T10 level after a 
single laminectomy.  B) Dorsal over hemisection injury made with a single 
cut to the spinal cord column.  C) Gel scaffold, embedded with chABC loaded 
microtubes, implanted on top of the lesion site.  D) The implanted hydrogel-
microtube delivery scaffold was covered with stiffer agarose gel to stabilize 








Table 1. Experimental design of  2 week study with notation 
Notation of 
groups 
Components # of rats 
MTC 
Agarose gel scaffold embedded with 




Agarose gel scaffold embedded with 
microtubes loaded with trehalose 
6 
STC Single injection of chABC with trehalose 8 
SC Single injection of chABC 6 
MTP 
Agarose gel scaffold embedded with 




Single injection of penicillinase with 
trehalose 
6 
NoT Injury and no treatment 6 
Sham 
Conducted the same procedure except 
injury with other groups 
4 
M: lipid microtubes, S: single injection, T: trehalose, C: chABC and P: penicillinase 
 
  
4.2.3 TISSUE PREPARATION AND IMMUNOHISTOCHEMISTRY OF SPINAL 
CORDS 
At two weeks post-surgery, the animals were perfused transcardially with 1X PBS 
followed by 4% paraformaldehyde in 1X PBS. The T9-T11 spinal cord was removed, post-
fixed in 4% paraformaldehyde and placed in 30% sucrose at 4 ºC until it sank to the bottom. 
Tissues were frozen in OCT and sagittal sections were cut with a cryostat (HM 560MV 
Cryostat) at 14 µm thickness. All sections were mounted in serial order onto charged 
microscope slides.  
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Sections were washed with 0.5% Triton X-100 PBS for 10 min and incubated with 4% 
of goat serum/0.5% Triton X-100 PBS (blocking solution) for 1 hour. The sections were 
incubated with primary antibodies diluted in blocking solution at 4 ºC overnight. The 
following primary antibodies were applied: an antibody to the stub protein after chABC 
digestion (1:150, mouse IgM, clone 3-B-3; Seikagaku America) which recognizes 
unsaturated, C6-sulfated glycosaminoglycan stubs (Baker et al., 1991); chondroitin sulfate 
proteoglycan (1:250, mouse IgM, clone CS-56; Sigma) to identify CSPGs; glial fibrillary 
acidic protein (GFAP) (1:600, polyclonal rabbit IgG; Chemicon) for astrocytes; and Wisteria 
floribunda agglutinin (WFA) (5 µg/ml, biotin conjugate; Sigma) for perineuronal nets. After 
primary antibody incubation, sections were washed three times with 0.5% Triton X-100 PBS 
and incubated with the appropriate secondary antibodies conjugated to fluorophores for 1 
hour at room temperature. The following secondary antibodies were used: goat anti-rabbit 
IgG(H+L) Alexa Fluor 488 (1:200 dilution in 0.5% Triton X-100 PBS; Invitrogen) for GFAP; 
goat anti-mouse IgM Alexa Fluor 594 (1:200) for 3B3 and CS-56; and streptavidin Alexa 
Flour 488 for WFA. Sections treated with secondary antibody but without primary antibody 
were used as staining controls. The sections were washed three times with 1X PBS and DAPI 
was applied to some of the sections for 15 min at room temperature to label the cell nuclei. 
The sections were washed twice with 1X PBS and then coverslipped using Fluoromount-G 
(Southern Biotechnology Associates, Inc.).  
To examine the effectiveness and enzymatic functionality of chABC delivered by 
hydrogel-microtube delivery system and single injection treatments, triple staining was done 
with 3B3, GFAP and WFA, and adjacent sections were double stained with CS-56 and GFAP. 
GFAP labeling was used to delineate the border of the astroglial scar lining the lesion site 
84 
 
(Fig. 4.4A). Images were taken on the Zeiss Axioskop 2 Plus microscope (Zeiss, Thornwood, 
NY) with an Olympus Microfire digital camera. 
 
4.2.4 QUANTITATIVE ANALYSIS OF CSPG DIGESTION AND ASTROCYTE 
RESPONSE 
Quantification of CSPG digestion 
To quantify the 3B3-immunoreactivity (IR) and CS-56-IR after chABC delivery 
around the lesion site, four or five micrographs were taken at 20x magnification along the 
lesion site as figure 4.4A. Relative to the lesion site, two caudal and two rostral images as 
well as one image underneath the lesion were used. At least four animals were chosen from 
each animal group and relative fluorescent intensity was measured using ImagePro software 
package (MediaCybernetics). The gross fluorescent intensity was measured for the region 
and a mean value was obtained and averaged for each animal. Background intensity was 
measured on each section and deducted from the measured 3B3-IR and CS-56-IR intensity. 
 
Quantification of GFAP 
To quantify the astrocyte responses, the spinal cord tissues were immunostained and 
imaged at 20x magnification along the lesion site with the same exposure time and conditions. 
The images were analyzed with a custom-built image analysis program (MATLAB; 
Mathworks) (Jain et al., 2006). This program generates line profiles radial to the defined 
interface and records the intensity of the fluorescent signal along the line profile, thus 
quantifying the relative value of intensity as a function of distance from the lesion interface 
(x=0) into the spinal cord (Fig. 4.4B). The number of line profiles (e.g. 30 lines), the color 
(one of RGB) to be read and the lesion interface can be selected by the user. With each run, 
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the relative intensity is averaged over all the line profiles. Four scans were performed for 
each staining image and the results were averaged again over all four scans. Four sections 
were chosen from each animal, four animals were chosen from each animal group and at 
least five images were captured. At least 80 images (five images X four spinal cord sections 
X four animals) were used and the relative intensity as a function of distance was averaged 
over 2400 (30 lines X 80 images) line profiles per experiment group. After this analysis, the 
relative intensity was compared between groups for different distances from the interface: 0-
100, 100-300 and 300-500 µm. 
 
  
Figure 4.4. Micrographs of the GFAP immunostained tissue and method of 
image analysis with a custom developed MATLAB program. A) 4x 
immunostained image. The solid line represents the lesion boundary defined 
by GFAP immunoreactivity and the boxed areas denote regions selected for 
quantification. Scale bar is 500 µm. B) One of the boxes in figure A is 
expanded at 20x magnification to show analysis of fluorescent intensity using 
line profiles. The X axis represents distance from the lesion interface in pixel 
unit. The lines were generated from the lesion interface into the tissue, 
averaged and displayed as a function of distance from the interface to between 





4.2.5 STATISTICAL ANALYSIS 
Minitab software was used to determine the statistical differences existing between 
experimental conditions using analysis of variance (ANOVA). A p-value <0.05 was 
considered statistically different.  
 
All animal protocols were approved by the Institutional Animal Care & Use 
Committee at Georgia Institute of Technology. Animal welfare, including pre-care, surgeries, 
pain management, post-care and monitoring was supervised by the Animal Research 
Committee of the Georgia Institute of Technology. 
 
4.3 RESULTS 
4.3.1 SUSTAINED DELIVERY OF ENCAPSULATED CHABC DIGESTS CSPGS 
EFFECTIVELY IN VIVO 
The effectiveness and enzymatic activity of trehalose stabilized chABC when 
delivered in vivo after SIC using our lipid microtube-embedded hydrogel delivery system at 
the lesion site (Fig. 4.1) was examined by CS-56 and 3B3 immunostaining. The 3B3 
antibody recognizes unsaturated, C6-sulfated glycosaminoglycan stubs (Baker et al., 1991) 
and therefore, can be used as a marker for CSPGs digested by chABC. The CS-56 antibody 
was used to identify intact CSPG deposition. GFAP immunoreactivity (GFAP-IR) was used 
to identify reactive astrocytes and in combination with either 3B3 or CS-56, to define the 
lesion boundary. Two weeks after hemisection SCI, tissue sections from the MTC (hydrogel-
microtube delivery scaffold loaded with 1M trehalose/chABC; See Table 1 for notation of 
groups) treated animals showed significantly strong 3B3-IR near the lesion site (Fig. 4.5E) 
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while CS-56-IR in adjacent tissue sections was diminished (Fig. 4.5D). CS-56-IR was strong 
along the lesion interface in most of the tissue sections, however intensity of CS-56-IR was 
significantly reduced overall for the region near the lesion with sustained chABC delivery. In 
the no-treatment (NoT) group, the reverse IR was observed with strong CS-56 intensity and 
no 3B3-IR (Fig. 4.5A and B).  Similar patterns were observed in the rest of the other control 
groups except the MTC group.  
To determine if chABC delivery affected the integrity of PNNs in the vicinity of the 
lesion site, PNNs were labeled with Wisteria floribunda agglutinin (WFA) cytochemistry in 
the same tissue sections that were stained with 3B3. WFA is a lectin specific for N-
aceylgalactosamine and results in visualizing net-like structures of PNNs. PNNs were 
observed near the lesion site in single injection-trehalose-chABC, no treatment (Fig. 4.5C) 
and other conditions except the MTC treated condition where significantly less WFA staining 
was observed (Fig. 4.5F). Immunostaining of WFA, 3B3, and CS-56 showed that WFA-
PNNs were present in conditions when CS-56-IR intensity was strong and 3B3-IR was weak 
or absent around the lesion site. In the MTC treated group, the 3B3 positive region where 
CSPGs were degraded by chABC had no WFA-PNNs and low CS-56-IR.  Therefore 
sustained delivery of chABC resulted in significantly diminished PNNs close to the lesion 













Figure 4.5. Immunohistological analysis of CSPG digestion in vivo (A-F). 
Images were taken right next to the lesion boundary of no treatment (A, B 
and C) and MTC treatment (hydrogel-microtube delivery scaffold loaded 
with chABC/ 1M trehalose; D, E, and F) animals. CS-56-IR for intact 
CSPGs (A and D). 3B3-IR for digested CSPGs (B and E). WFA staining for 
perineuronal nets (C and F). The intensity of CS-56-IR and WFA is 
inversely proportional to 3B3-IR. Arrows in (C) indicate WFA-PNNs. Scale 











4.3.2 QUANTIFICATION OF 3B3, CS-56 AND GFAP IMMUNOSTAINING 
Measurements of fluorescent pixel intensity were as used to quantify 3B3, CS-56 and 
GFAP immunostaining (Fig. 4.6) using an ImagePro software and a custom-built MATLAB 
routine. 3B3-IR is significantly higher in the MTC group as compared to all other groups 
(Fig.4.6A, p<0.05). The average CS-56-IR is significantly lower in the MTC group than 
others and there is a statistical difference for CS-56-IR between MTC and no-treatment 
(NoT); MTC and STP (single injection-trehalose-P‟ase) (Fig. 4.6B, p<0.05).  
GFAP-IR positive astrocytes were used to define the astro-glial scar region and the 
boundary of the lesion site (Fig. 4.4A). The fluorescent pixel intensity was quantified with a 
line profile image analysis program developed in MATLAB (Fig. 4.4B; Jain et al., 2006); the 
program measures intensity changes from the lesion interface into the spinal cord radially. 
The intensity of GFAP-IR decreased from the lesion site into the cord and the number of 
reactive astrocytes also decreased, and correlated positively with CS-56-IR intensity. 
Analyzed intensity was divided into three bins, 0-100, 100-300 and 300-500 µm away from 
the lesion interface. The GFAP-IR was lower in the MTC treated group than other groups, 
and there is a significant difference between the MTC treated group and other groups; NoT, 
STP and MT in 0-100 µm and 100-300 µm (Fig. 4.7, p<0.05). This data confirm that our 
sustained delivery system using lipid microtubes embedded in agarose hydrogel does not 





      A                    3B3 
 
       B                   CS-56 
Figure 4.6. Quantitative image analysis of 3B3-IR and CS-56-IR fluorescent intensity. 
The X axis represents each experimental condition treated for animal groups. The Y 
axis represents the relative fluorescent intensity of IR. The relative fluorescent 
intensity was measured alone the lesion boundary, and mean value was obtained and 
averaged for each animal. (A) 3B3-IR quantitative analysis. Asterisk denotes 
significant increase of 3B3-IR in MTC treatment compared to all other treatments 
(p<0.05). (B) CS-56-IR quantitative analysis. Asterisks denote significant decrease of 
CS-56-IR in MTC treatment when compared to NoT and STP treatments (p<0.05). 
No significant differences were observed among other treatments. The data represent 









































                       Distance from the lesion site (µm) 
Figure 4.7. Quantitative image analysis of GFAP-IR fluorescent intensity by line 
profile. The X axis represents distance from the lesion interface into the spinal cord in 
µm and 0 represents the lesion interface delineate the border of the astroglial scar 
lining the lesion site. The Y axis represents the relative fluorescent intensity of 
GFAP-IR. Overall the intensity of GFAP-IR decreased from the lesion interface into 
the cord as a function of distance. The GFAP-IR was lower in the MTC treated group 
than other control groups. The IR intensity was analyzed by dividing into three bins, 
0-100, 100-300 and 300-500. Asterisks denote a significant difference between the 
MTC treated group and other control groups; NoT, STP and MT in 0-100 µm and 





























The thermal instability of chABC represented a significant impediment to 
regeneration after SCI, as it limited drug delivery approaches and forced the use of infusion 
pumps or catheters for delivery.  In this study, we demonstrate that the enzymatic activity of 
chABC could be maintained at 37 ºC by adding trehalose and that thermostabilized chABC 
delivered by a lipid microtube-hydrogel scaffold system remains enzymatically active for at 
least two weeks in vivo.  This study therefore demonstrates that a single treatment with of the 
hydrogel-microtube system provides an effective and creative alternative to chronically 
implanted, invasive pumps/catheters that are typically used to deliver chABC in vivo. 
Given that astro-glial scar deposition spans a period of 2 to 4 weeks post-injury, 
clinical application of chABC might require enzymatic activity over a period of weeks. Most 
studies to date have delivered chABC via multiple intrathecal injections to achieve prolonged 
action. The time required to reach peak deposition of CSPG at the lesion site is dependent on 
the type of CSPG (Jones et al., 2003). NG2 is the predominant CSPG expressed after SCI 
and reaches peak deposition between 1 and 2 weeks after injury, and the expression levels of 
neurocan, brevican, and versican are elevated after SCI, peak at 2 weeks and are maintained 
for 4 weeks or more. The production of several CSPGs and proteoglycan species is 
differently affected by degree and type of spinal cord injury. The main deposition pattern is 
that CSPG molecules are significantly elevated within 24 hours, slowly increase until they 
peak and then decrease, and overall CSPG-rich matrix persists up to 2 months. We chose a 
time point of 14 days after surgery to analyze the effectiveness of thermostabilized chABC 
and our delivery system because overall CSPG expression levels are highest at 14 ~ 18 days 
and decrease by 49 days (Iseda et al., 2008).  Delivery of active agents during this period 
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would be expected to affect inflammation and cellular responses, modulate CSPGs 
deposition around lesion site, and promote axonal sprouting and outgrowth. 
The sustained and local delivery of chABC was achieved over a 2 week time period 
using a previously characterized gel scaffold system in our laboratory. It has been 
demonstrated that agarose hydrogel-lipid microtube-based delivery acts as a sustained 
delivery system in vitro with various proteins and DNA (Meilander et al., 2001; Meilander et 
al., 2003).  An in situ technique is used to quickly cool and set the liquid gel, and this gel 
cooling system (Fig. 4.2) allows the gel to mold into the shape of the injury site. A BDNF-
loaded hydrogel-lipid microtube delivery scaffold was used to fill the lesion cavity on the 
dorsal column of the spinal cord (Jain et al., 2006), and methylprednisolone-loaded 
biodegradable PLGA nanoparticle-hydrogel was topically delivered to the contusion -injured 
spinal cord as described in figure 4.1 (Chvatal et al., 2008; Kim et al., 2009). This gel-
microtube system also can be combined with a conduit to provide a bridge with neurotrophic 
factors for peripheral nerve regeneration (Dodla and Bellamkonda, 2008). The previous 
studies and this study demonstrate that our gel-microtube based delivery system does not 
aggravate inflammatory responses compared to control groups. By implanting the stabilized 
chABC sustained delivery scaffold on the top of the lesion site, we avoid a second surgery 
that could cause additional injury and stress to the animal. We also avoid a chronically 
inserted catheter/mini-pump that could induce inflammatory mass and increase infection risk 
(Penn, 2003; Peng and Massicotte, 2004).  
In the MTC treated group, 3B3-IR is significantly higher compared to all other groups. 
As a control, to compare the effect of sustained delivery versus single administration, a dose 
of thermostabilized chABC (STC) equal to the total amount of chABC released from the 
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lipid-microtubes over 14 days was injected at the lesion site.  This single injection had no 
effect as determined by a lack of 3B3 staining.  This data indicates that indeed sustained 
release of chABC is critical either because chABC diffuses away and loses its enzymatic 
activity quickly after the single injection, or because CSPGs continue to be produced over 
time. In the MTC treated group, 3B3-IR is significantly higher compared to all other groups. 
It is interesting that in the STC group, small bright spots of 3B3-IR were observed around the 
lesion site (gray matter) possibly due to chABC digesting some CSPGs before being washed 
out. Once CSPGs are digested, the turn-over is relatively slow. PNNs were also degraded by 
the digestion of CSPGs following microtube-mediated release of chABC.  In comparison, a 
single injection of chABC was not sufficient to break-down PNNs.  In the MTC treated 
spinal cord, PNNs were not observed immediately around the lesion site, but PNNs were 
present approximately 1 mm away from the lesion site suggesting that thermostabilized 
chABC activity was localized to the region in the immediate vicinity of the lesion.  
Permissive environment  
Another consequence of chABC treatment is the effects of the disaccharidic 
degradation products of CSPG generated by chABC digestion. The disaccharidic by-product 
protects neurons against inflammation-induced neurodegeneration by down-regulating T cell 
motility and decreasing cytokine secretion such as interferon-γ and tumor necrosis factor-α 
(Rolls et al., 2006). The by-product modulates intracellular signaling pathways such as PKCα 
and PYK2, and induces neuronal outgrowth and protects neurons against neuronal toxicity 
(Rolls et al., 2004). In this study, GFAP-IR quantification demonstrates that a) there is no 
elevation of inflammation response in gel scaffold treated groups, and b) GFAP-IR was 
significantly lower in the MTC treated group than others (NoT, STP and MT) near the lesion 
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area (Fig. 4.7). Therefore, it is possible that chABC treatment generated disaccharidic 
degradation products act as neuroprotective agents and trigger neuronal protective and 
survival signaling pathways. 
 
4.5 CONCLUSIONS 
In conclusion, this study clearly demonstrates that sustained local delivery of 
thermostabilized chABC digests CSPGs after SCI without aggravating the secondary injury 
response. Combinational therapy of chABC and neurotrophic factors via our delivery system 
could provide a synergic effect on axonal regrowth and functional recovery after SCI. This 
approach obviates the need for invasive, pump mediated delivery of chABC, elegantly 
enhances the thermostability and resultant efficacy of chABC in vivo, and overcomes an 
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DELIVERY OF THERMOSTABILIZED CHABC AND NT-3 AND EVALUATION 
OF AXONAL REGENERATION AND FUNCTIONAL RECOVERY AFTER SPINAL 
CORD INJURY:  LONG TERM STUDY 
(Partially as published with R.J. McKeon and R.V. Bellamkonda, Proceedings of the 
National Academy of Science, 2009) 
 
CSPGs are one major class of axon growth inhibitors which are upregulated after SCI 
and contribute to regenerative failure. Chondroitinase ABC (chABC) digests CS-GAG chains 
on CSPGs and can thereby overcome CSPG mediated inhibition and promote axonal 
regeneration when delivered at the site of injury. However, chABC loses its enzymatic 
activity rapidly at 37 ºC, necessitating the use of repeated injections or local infusions with a 
mini-pump or catheter for days to weeks. Maintaining these infusion systems is invasive, 
infection-prone and clinically problematic. To overcome this limitation, we thermostabilized 
chABC and developed a system for its sustained local delivery in vivo, obviating the need for 
chronically implanted catheters and pumps in chapter 3.  When stabilized with trehalose, 
chABC remained active at 37 ºC in vitro for up to 4 weeks. A lipid microtube-agarose 
hydrogel system was used for controlled release of chABC over 2 weeks at the lesion site 
following a SCI in chapter 4. The enzymatic functionality of released chABC and the cellular 
and molecular responses were examined by immunostaining with 3B3, CS-56, GFAP and 
WFA two weeks after injury. The results demonstrate significant differences in CSPG 
100 
 
digestion between groups treated with the chABC-loaded hydrogel microtube delivery 
system and controls. 
In this chapter, a long term study (45 days) was conducted to examine axonal 
regeneration and functional recovery after chABC treatment and combination treatment with 
a neurotrophic factor, NT-3. The resultant impact of the initial CSPG digestion during the 
first two weeks was still present at 6 weeks following SCI when delivered by a hydrogel-
microtube delivery system. Axonal growth and functional recovery following the sustained 
local release of thermostabilized chABC versus a single treatment of unstabilized chABC 
demonstrated significant differences in CSPG digestion. Additionally, animals treated with 
stabilized chABC in combination with sustained NT-3 delivery showed significant 
improvement in locomotor function, enhanced growth of CTB-positive sensory axons, and 
sprouting of 5-HT serotonergic fibers at the lesion site. We suggest that this significant 
improvement of chABC thermostability facilitates development of a minimally invasive 
method for sustained, local delivery of chABC that is potentially effective in overcoming 
CSPG-mediated regenerative failure. Combination therapy of thermostabilized chABC and 
neurotrophic factors enhances axonal regrowth, sprouting and functional recovery after SCI. 
 
5.1 INTRODUCTION 
After injury to the central nervous system, the lesioned axons fail to re-grow or make 
functional connections (Schwab and Bartholdi, 1996). While the cellular and molecular 
mechanisms of axon growth failure are active areas of research, a breakthrough clinical 
therapy has yet to be developed. Injuries to the CNS induce a series of inflammatory events 
around the lesion site, typically resulting in permanent functional loss.  
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There are many factors contributing to the failure of spontaneous regeneration; a lack 
of sufficient neurotrophic support (Widenfalk et al., 2001), a lack of intrinsic regeneration 
capacity in CNS as compared to PNS microenvironment (Neumann and Woolf, 1999), 
inhibitory molecules such as myelin-associated proteins (Filbin, 2003; Schwab, 2004; 
Schwab et al., 2006) and glial scar-associated CSPGs (McKeon et al., 1995; Silver and Miller, 
2004), which are upregulated after injuries to the CNS and contribute to regenerative failure. 
Strategies can be developed for each inhibitory factor to overcome the lack of repair capacity 
after spinal cord injury. In chapter 3 and 4, we focused on developing a chABC treatment to 
attenuate CSPG-mediated failure of axonal regeneration and provide permissive substrates 
prepared by chABC digestion for axonal outgrowth.  
In this chapter a combination strategy was developed to provide a neurotrophic factor 
for chemo-attracting axons to the lesion site. Combination therapies with chABC have been 
previously investigated. Schwann cell-seeded guidance channels were implanted into 
hemisected adult rats after chABC treatment (Chau et al., 2004) and an autologous peripheral 
nervous system bridge with cellular matrix modified by chABC was grafted onto a 
hemisection lesion (Houle et al., 2006). Synergistic effects were observed on axonal 
sprouting into the dorsal column nuclei after combination treatment with chABC and NT-3 
(Massey et al., 2008). Retinal fiber sprouting with combination treatment with chABC and 
BDNF after denervation of the superior colliculus has been also observed (Tropea et al., 
2003). To encourage axonal outgrowth, we chose to use NT-3 with chABC. Removal of an 
unfavorable environment (CSPG) by chABC and presentation of the supporting neurotrophic 
factor NT-3 was expected to be a promising combination for SCI. 
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A longer 45 day study was designed to examine the functional consequences of 
CSPG digestion by chABC and a combination therapy with the neurotrophic factor NT-3 via 
implantation of a hydrogel-lipid microtube delivery system at the lesion site. We 
demonstrated that the enzymatic activity of chABC can be thermostabilized at 37 ºC due to 
the ability of trehalose to confer conformational stability, and that thermostabilized chABC 
delivered by a lipid microtube-hydrogel scaffold system is enzymatically active in situ for at 
least 2 weeks as described in Chapters 3 and 4.  Here, a combination treatment of 
thermostabilized chABC and NT-3 was used to overcome the CSPG-rich astroglial barrier to 
axonal regeneration and encourage axonal outgrowth. Locomotor behavioral improvements 
with combination delivery of chABC and NT3 were observed, and correlated well to 
immunohistological evidence of axonal sprouting at the lesion site. Analysis of 5-HT sensory 
fibers and CTB-labeled fibers demonstrated that chABC treatment can induce plasticity of 
injured projections within the spinal cord and offers a possible mechanism of chABC-
induced functional recovery. This study therefore demonstrated that a single administration 
of the hydrogel-microtube delivery system provides an effective alternative to chronically 
implanted, invasive catheters or mini-pumps typically used to deliver chABC after SCI. The 
combination therapy of chABC and NT-3 with our delivery method offers a potent approach 
for clinical application after SCI. 
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5.2 MATERIALS AND METHODS 
5.2.1 TOPICAL DELIVERY OF HYDROGEL-MICROTUBE SCAFFOLDS IN A 
DORSAL OVER HEMISECTION MODEL 
Table 5.1 describes conditions and notations of experimental and control groups in 
the 45 day in vivo study. In the long term study, MTC (hydrogel-microtube delivery scaffold 
loaded with 1M trehalose/chABC; n=7), MTP (hydrogel-microtube delivery scaffold loaded 
with 1M trehalose/P‟ase; n=6) and sham (n=4) treatment conditions were used, the other 
conditions used in the short term study were excluded, and three new treatments were added. 
In the short term study, a single injection of chABC did not show effective digestion of 
CSPGs, and there was no significant difference from no treatment animals in the 2 week 
study (in chapter 4, section 4.3.2). Therefore, single injection controls (SC – single injection 
of chABC, STC – single injection of 1M trehalose/chABC, STP – single injection of 1M 
trehalose/P‟ase) were excluded.  
MTN (hydrogel-microtube-1M trehalose/NT-3), MTCN (hydrogel-microtube-1M 
trehalose/chABC and 1M trehalose/NT-3) and GC (hydrogel mixed with an equal amount of 
1M trehalose/chABC to the MTC treatment condition) treatment conditions were added for 
the long term study. As a control to probe the sustained release enabled by lipid microtubes 
embedded in the hydrogel, 1 % of SeaPrep agarose gel mixed with 10 mU of chABC/1M 
trehalose was implanted on the top of the lesion site (n=6; GC); the other conditions included 
lipid microtubes loaded with NT-3 (n=7; MTN; 100 ng per rat) or combination microtubes 
loaded with chABC and NT-3 (n=8; MTCN) to investigate effect of combination treatment 
of chABC and neurotrophic factor. 
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The surgical procedure followed to induce injury and the delivery methods of 
hydrogel-microtubes delivery scaffold were the same as for the 2-week short term study 
described in the chapter 4, section 4.2.2. Briefly, adult male Sprague-Dawley rats (Charles 
River) received a dorsal over-hemisection injury at the T-10 vertebral level. Sustained topical 
delivery was achieved using methods previously reported (Chvatal et al., 2008) and shown in 
the figure 4.1 and figure 4.3. 
 
5.2.2 RETROGRADE NEUROAL TRACER INJECTION INTO THE SCIATIC NERVE 
Six weeks post-injury and 3 days before sacrificing, cholera toxin B subunit (CTB; 
sigma) was injected into the right sciatic nerve for retrograde axonal tracing. Rats were 
anesthetized using isoflurane gas. The thigh region on the right leg was shaved, and 2 cm of 
incision was made through the skin and muscles to expose the sciatic nerve. 5 µl of 1% CTB 
was slowly injected into the nerve with a 34 gauge needle (NanoFil). The muscles were 
sutured and the skin closed using wound clips. 3 days after injecting the CTB, the animals 
were the animals were anesthetized with a ketamine-xylazine-acepromazine cocktail 
(1:0.17:0.37 ml/kg) and perfused transcardially with PBS followed by a mixture of 4% 














M: lipid microtubes, S: single injection, T: trehalose, C: chABC and P: penicillinase 
 
5.2.3 BEHAVIORAL ANALYSIS 
Locomotion and thermal pain sensitivity were assessed to determine functional 
improvement in the 45 day long term study. The investigators were blinded with regard to 
animal groups throughout these tests. CatWalk (Noldus), a video-based analysis system, was 
used to assess locomotor deficits in voluntarily walking. Each rat voluntarily walked across 
the walkway three times every week after injury. After acquiring raw data, paw prints were 
labeled as right forepaw (RF), left forepaw (LF), right hindpaw (RH) and left hindpaw (LH) 
and measurements of locomotion were provided by the software. Stride length, paw print 
pattern and base support were chosen to examine behavior as a function of time after injury 
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Conducted the same procedure except 




for all experimental conditions. Stride length was defined as a distance between consecutive 
steps with the same limb. The distance in mm between the two hind paws was defined as the 
base of support and this distance is measured perpendicular to the direction of walking. The 
white boxes in figure 5.1 show abnormal hindpaw print patterns and the number of abnormal 
prints was counted for three step cycles.  
 
Figure 5.1. CatWalk raw data in false color mode. White boxes represent 
abnormal hindpaw print patterns. The dotted lines represent the stride length 
defined as a distance between consecutive steps with the same limb and the 
solid line represents the base of support defined as a distance between the two 
hind paws. (dark red – left hindpaw, light red – left forepaw, dark green – right 
hindpaw and light green – right forepaw) 
 
Thermal sensitivity assessment by a dynamic plantar test (Ugo Basile) was used, 
identical to the method of Hargreaves et al (1988). The device measured the time taken to 
elicit a flexion reflex. Each hind-paw was tested three times every week and averaged. The 
animals were placed on a glass floor under which a mobile radiant infra-red heat source was 
positioned at the animal‟s hind paw. When the animal withdrew its paw, the source power 
turned off, triggered by an automatic sensor.    
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5.2.4 TISSUE PREPARATION AND IMMUNOHISTOCHEMISTRY 
At 45 days post-surgery, the animals were perfused transcardially with PBS followed 
by 4% paraformaldehyde in PBS. The T9-T11 spinal cord was retrieved, post-fixed in 4% 
paraformaldehyde and placed in 30% sucrose at 4 ºC. Tissues were frozen and sagittal 
sections were cut with a cryostat (HM 560MV Cryostat) at 14 µm thickness. All sections 
were mounted in serial order onto charged microscope slides. 
Sections were washed with 0.5% Triton X-100 PBS for 10 min and incubated with 4% 
of goat serum/0.5% Triton X-100 PBS (blocking solution) for 1 hour. The sections were 
incubated with primary antibodies diluted in the blocking solution at 4 ºC overnight. The 
following primary antibodies were applied against: CS-56 (1:250, mouse IgM; Sigma) to 
identify CSPGs; glial fibrillary acidic protein (GFAP) (1:600, polyclonal rabbit IgG; 
Chemicon) for astrocytes; anti-CTB (1:600; abcam); and serotonin (1:150, 5-HT, monoclonal 
mouse IgG1; Abcam) for serotonergic neurons. After primary antibody incubation, sections 
were washed three times with 0.5% Triton X-100 PBS and incubated with the appropriate 
secondary antibodies conjugated to fluorophores for 1 hour at room temperature. The 
following secondary antibodies were used: goat anti-rabbit IgG(H+L) Alexa Fluor 594 
(1:200 dilution in 0.5% Triton X-100 PBS; Invitrogen) for GFAP; goat anti-mouse IgM 
Alexa Fluor 488 (1:200) for anti-CTB, 5-HT serotonin and CS-56. Sections treated with 
secondary antibody but without primary antibody were used as staining controls. The 
sections were washed three times with PBS and coverslipped using Fluoromount-G. 
To evaluate the axonal sprouting, double staining was conducted with CTB and 
GFAP or 5-HT and GFAP. Double staining of 3B3 and GFAP was also conducted to 
examine the level of CSPGs. GFAP labeling was used to define the border of the astroglial 
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scar lining the lesion site (Fig. 4.4A). Images were taken on the Zeiss Axioskop 2 Plus 
microscope with an Olympus Microfire digital camera. 
 
5.2.5 QUANTITATIVE ANALYSIS OF AXONAL SPROUTING 
A montage of each tissue section stained for CTB labeled fibers was obtained at 10x 
magnification using Neurolucida software (MicroBrightField Bioscience). The 0 indicates 
the caudal lesion interface and defined by GFAP immunoreactivity (IR). The relative 
intensity of CTB labeled fibers were measured using ImagePro software (MediaCybernetics) 
at 1 and 0.5 mm caudal to the start of lesion, at the start of the lesion, and 0.5 and 1 mm 
rostral to the lesion. The intensity of CTB labeled fibers 1 mm caudal to the caudal edge of 
the lesion was assumed to represent the total CTB fibers approaching the lesion site and the 
percentage of CTB fibers stopped within the defined regions was determined by measuring 
the relative intensity. Background intensity was measured on each section and deducted from 
the measured CTB intensity.  
To quantify 5-HT serotonin immunofluorescence, micrographs were taken at 20x 
magnification from two defined regions, ventral gray matter caudal and rostral to the lesion 
site, and relative fluorescent intensity was measured by ImagePro software package. The 
gross fluorescent intensity was measured for the region and mean value was obtained. 







5.2.6 STATISTICAL ANALYSIS 
Minitab software was used to determine the statistical differences existing between 
experimental conditions using analysis of variance (ANOVA). A p-value <0.05 was 
considered as statistically different.  
 
All animal protocols were approved by the Institutional Animal Care & Use 
Committee at Georgia Institute of Technology. Animal welfare, including pre-care, surgeries, 
pain management, post-care and monitoring was supervised by the Animal Research 




5.3.1 LEVELS OF CSPG DEPOSITION AFTER SUSTAINED DELIVERY OF CHABC 
AT 6 WEEKS 
To examine whether the resultant impact of the initial 2 weeks of CSPG digestion 
persists in vivo after 6 weeks, CS-56 immunostaining for intact CSPGs was conducted. Tissue 
sections from the MTCN treated animals showed that significantly less CS-56 expression 




      
Figure 5.2. Micrograph of CS-56-IR around the lesion site at 6 weeks. (A) 
MTCN and (B) MTP. CSPG-IR is significantly less in the MTCN treated 
animals compared to MTP treated controls. Scale bar is 100 µm.   
 
5.3.2 SUSTAINED DELIVERY OF CHABC AND NT-3 IMPROVES LOCOMOTOR 
FUNCTION 
Functional recovery was assessed by using the CatWalk
TM
 and thermal plantar tests 
throughout the 45 day period. A significant difference in locomotor function was observed 
six weeks post-injury, but not earlier, and no improvement was observed with the thermal 
pain threshold test in any animal groups throughout the six week testing period.  All the 
animal groups showed improved locomotor function throughout the testing period. At day 7 
and day 14, all animals showed abnormal walking patterns, slow crossing, and abnormal paw 
prints, reflecting the SCI-mediated dysfunction. Four weeks post surgery, most animals 
showed a normal step sequence and the time necessary to cross the walkway decreased. A 
number of abnormal hind paw prints also decreased and stride length increased due to 




Figure 5.3 showed CatWalk raw data of sham (A), MTCN (B) and MTP (C) treated 
animals on the walkway in false color mode at 6 weeks. Dark red represents left hindpaw; 
light red – left forepaw, dark green – right hindpaw and light green – right forepaw. As seen 
on figure 5.3, hindpaws step on the print of the consecutively previous forepaw. Animals 
with higher degree injuries generally fail to walk with a normal step sequence and step on the 
consecutively previous forepaw print. In this study, we used a relatively moderate injury 
(dorsal over hemisection), therefore, most animals showed normal step patterns. Six weeks 
post-SCI surgery, there were significant differences in the stride length between treatment 
conditions (Fig. 5.4). Average stride lengths (mean ± SEM) were 183.6 ± 6.91 mm for 
MTCN, 172.89 ± 20.8 mm for MTC, 157 ± 18.25 mm for MTN, 152.91 ± 13.13 mm for GC 
and 154.07 ± 10.11 mm for MTP at 6 weeks (See Table 2 for notation of groups). Significant 
differences were observed between MTCN and GC (p = 0.019), and MTCN and MTP (p = 
0.035).  
At 6 weeks, the MTCN, MTC and MTN treated animals had more normal foot prints 
(Fig. 5.3B) compared to MTP treated animals (white boxes in Fig. 5.3C). The sham animal 
had normal foot print and the MTP animal had abnormal hindpaw prints (white box in Fig. 
5.3C.). The number of abnormal hindpaw prints was counted per three step cycles and the 
averages were 0.7 ± 0.3 for MTCN, 1.7 ± 0.6 for MTC, 1.8 ± 0.5 for MTN, 2.1 ± 1.3 for GC 
and 3.3 ± 1.3 for MTP. The mean number of abnormal print of the single treated animals, 
MTC and MTN, is less than that of animals treated by GC and MTP and the combination 
treatment MTCN group, on average had even fewer abnormal foot prints.  However while 
these were strong trends, the differences were not significant between animal groups.  
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The distance in mm between the two hind paws was defined as the base of support 
and this distance is measured perpendicular to the direction of walking. Animals tend to 
show a larger base of support after SCI. At 6 weeks, the averages were 31.4 ± 4.8 mm for 
MTCN, 30.7 ± 4.4 mm for MTN, 39.8 ± 8.9 mm for GC and 38.5 ± 4.5 mm for MTP, and 








Figure 5.3. CatWalk raw data in false color mode, (A) Sham, (B) MTCN 
and (C) MTP treated animals on the walkway at 6 weeks. All animal 
groups show a normal step sequence. The white box in the figure C 
represents an abnormal hindpaw print. Red represents left paw prints and 
green represents right paw prints (dark red – left hindpaw, light red – left 










Figure 5.4. Stride length analysis for locomotion functional recovery. Data are 
mean ± SEM and asterisk denotes statistical significance between MTCN and 
MTP, and between MTCN and GC (P <0.05). Sham showed significant 
differences († < 0.05) compared to all other conditions throughout the testing 

































5.3.3 SUSTAINED DELIVERY OF CHABC AND NT-3 PROMOTES SPROUTING 
5.3.3.1 AXONAL SPROUTING AROUND THE LESION AREA: CTB-LABELED 
FIBERS 
To examine anatomical regeneration in the dorsal column, CTB was injected into the 
sciatic nerve and resulted in labeling of the primary apparent within the spinal cord. The 
location of labeled fibers was examined; the MTP and GC treated animals had retracted 
CTB-labeled fibers in the glial scar area and few fibers approached the lesion site (Fig. 5.5A). 
However in the MTC, MTN and MTCN treated animals, more CTB-labeled fibers crossed 
the glial scar area and approached the lesion boundary (Fig. 5.5B). CTB-labeled fibers grew 
around cavities along the lesion interface (Fig. 5.5C and D; 0 to 0.5 mm interval in C and 0.5 
to 1 mm interval in D) and a few fibers were observed after 0.5 mm rostral to caudal edge of 
the lesion in chABC and NT-3 treated animals. However no fibers entered the lesion cavity 
in any animal groups. Significantly more fibers crossed 0 and 0.5 mm rostral to the caudal 
edge of the lesion in the MTCN (p=0.03 and p=0.045; p=0.049 and p=0.045, respectively) 
animals compared to GC and MTP treated animals (Fig. 5.6). At one mm rostral to the caudal 
edge of the lesion start, a few fibers were observed in the MTC, MTN and MTCN treated 
animals, however most were not strong enough to be detected by the relative intensity 






Figure 5.5. Micrographs of CTB labeled fibers (green) at the lesion site at 
6 weeks. The dashed lines represent the lesion interface. (A) MTP and (B) 
MTCN at 10 x magnification. Scale bar is 500 µm (C) An expanded figure 
from the white box 0 to 0.5 mm interval in figure A, and (D) an expanded 
figure from the white box in 0.5 to 1 mm interval figure B at 20 x 









Figure 5.6. Quantification of CTB+ axon growth. The Y axis represents 
the percentage of crossed axons at the distance to the lesion interface and 
the X axis represents distance to the lesion (mm). The data represent the 





































5.3.3.2 AXONAL SPROUTING AROUND THE LESION AREA: 5-HT- 
IMMUNOREACTIVE FIBERS 
5-HR-IR fibers in the ventral gray matter were measured to quantify the percentage of 
the lesion site. More 5-HT-IR fibers were observed in the gray matter of MTC, MTN and 
MTCN treated animals. The serotonergic fibers were observed in the gray mater, primarily in 
the ventral horn and lamina X, and more fibers were located rostral versus caudal to the 
lesion (Fig. 5.7A). The spinal cords tissues treated with chABC, NT-3 and combination of 
chABC and NT-3 had higher fluorescent intensity and the 5-HT-IR fibers extended closer to 
the lesion site than MTP and GC treated controls. Quantification confirmed that MTCN 
treatment showed significant sprouting of serotonergic fibers caudal to the lesion versus all 
other conditions (p = 0.008 for MTC, p = 0.024 for MTN, p = 0.001 for GC and p = 0.001 for 
MTP); and rostral to the lesion than MTN (p = 0.015), GC (p = 0.002) and MTP (p = 0.001) 
treatment (Fig. 5.8).   
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Figure 5.7. Immunohistological analysis of 5-HT-IR fibers. (A) 
Micrograph of 5-HT at 4× magnification in the MTCN treated animal 
tissue. The boxed areas in A denote regions selected for quantification and 
the solid white line represents the lesion interface. More fibers were 
located rostral versus caudal to the lesion. Scale bar is 500 µm. (B, C) 
Expanded figures from the white box in figure A. Serotonergic 
innervations rostral to the lesion in MTP (B) and MTCN (C) animals at 
20× magnification. MTCN treated animal has higher fluorescent intensity 
and also had extended closer to the lesion site than MTP treated animal. 












Figure 5.8. Quantitative analysis of 5-HT-IR intensity for the stained 
spinal cord. Quantification demonstrated that caudal to the lesion, MTCN 
showed significantly (* p <0.05) increased 5-HT-IR compared to all other 
treatments, and rostral to the lesion, MTCN showed significantly (* p 
<0.05) increased 5-HT-IR compared to all other treatments except for 





































A six week long term study was performed to determine whether chABC or NT-3 
delivered individually by using the hydrogel-microtube delivery system would encourage 
axonal sprouting/regeneration and improve functional recovery after SCI in the rodent model. 
Also, combination treatment of chABC and NT-3 was tested via our delivery system to 
evaluate whether the combination therapy can provide synergic effect on axonal regrowth 
and functional recovery. CSPG deposition, axonal sprouting and behavioral improvement 
were assessed to determine efficacy of the hydrogel-microtube delivery system and 
combination therapy. CS-56 immunostaining shows that the resultant impact of the initial 
CSPG digestion is still present at 6 weeks. Locomotor behavior improved with combinational 
chABC-NT3 delivery, and correlated well with increased axonal sprouting at the lesion site. 
This study demonstrates that a single treatment of thermostabilized chABC via the hydrogel-
microtube delivery system provides an effective alternative to chronically implanted, 
invasive pumps typically used to deliver chABC in vivo. In addition, the combination 
treatment with NT-3 significantly enhanced functional recovery. 
Once CSPGs are digested, the turn-over is relatively slow (Bruckner et al., 1998). In 
the short term study, significantly decreased CSPG-IR was observed in the animals treated 
with the chABC loaded hydrogel-microtube system. CS-56 immunostaining was performed 
to examine whether CSPG digestion during the first two week still present. CS-56 staining at 
6 weeks (Fig. 5.2) shows that little CS-56 expression persists compared to untreated controls. 
This suggests that thermostabilized chABC digestion was effective early, at the peak of 
CSPG production and its turn-over is slow (more likely), or that chABC activity via 
microtubes is sustained for longer than 2 weeks (unlikely, but possible).  In either case, the 
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chABC digestion via microtubes remains effective over a period of 6 weeks as is evident 
from little CS-56 positive tissue at the 6 week time point.  CSPG levels remain low up to 6 
weeks post-injury, thereby facilitating sprouting and regeneration. Another study reported 
similar results, showing that evidence of chABC digestion remained for at least 7 weeks in 
the spinal cord (Galtrey et al., 2007). 
The results demonstrated that a single treatment of chABC and NT-3 enhanced 
sensory axonal sprouting, and the combination treatment enhanced more axonal sprouting 
around the lesion site. The CTB labeled fibers mainly represent ascending sensory pathways 
in the dorsal columns of the spinal cord. No CTB-labeled fibers entered the lesion cavity in 
any treatment condition, however a significantly higher percentage of axons were approached 
the lesion boundary and grew around the lesion site in the animals treated with single or 
combination delivery of chABC and NT-3 compared to other groups. While some sensory 
functional recovery was expected because of the result of CTB-fiber quantification, no 
improvement was observed using the thermal pain threshold test (hindpaw withdrawal 
latency to heat stimuli) in any of the animal groups during the 45 day test period. There are 
two possibilities to explain the results; first, after the dorsal over hemisection cutting there 
may be possibly spared fibers around the dorsal lateral fasciculus that help retain sensitivity 
in all groups independent of lesion.  Second, despite the significant primary afferent 
sprouting in the treated animals, the sprouting was predominantly located in the dorsal white 
matter and no fiber entered into the lesion site in any animal groups. Therefore, the axonal 
sprouting was not enough to transmit stimuli to the dorsal horn where primary afferent 
terminals are located, explaining why no differences exist between experimental groups. Our 
observation is consistent with other studies. Despite robust primary afferent sprouting in 
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animals treated with chABC, no improvement of noxious thermal sensation (Barritt et al., 
2006) was observed, and transgenic mice expressed chABC under the murine gfap promoter 
showed nearly complete digestion of CSPGs and robust axonal growth into the glial scar, but 
no axon crossing into the lesion or motor functional recovery (Cafferty et al., 2007).  
Enhanced locomotor functions were observed in the MTC and MTCN animal groups 
and there were significant improvements in MTCN treated animals in terms of stride length, 
but not base support or number of abnormal hindpaw patterns. Stride length is an important 
parameter of locomotor efficacy as it impacts speed of locomotion (Hamers et al., 2001). The 
gains in other locomotor functions were probably obscured by our choice of the relatively 
mild hemisection injury model. Quantification of 5-HT serotonergic fiber sprouting 
demonstrated significantly higher sprouting in MTCN group relative to all other groups. As 
microtube-mediated delivery resulted in significant sprouting, with combinatorial delivery 
eliciting even more significant sprouting, it is possible that the sprouted local serotonergic 
spinal circuits facilitated observed locomotor improvements in stride length. This increase in 
sprouting is likely due to chABC mediated digestion of CSPG-rich PNNs that surround 
synapses (Vitellaro-Zuccarello et al., 1998). One of consequence of the chABC treatment is 
the digestion of CSPG-rich perineuronal nets (PNNs) (Massey et al., 2006; Galtrey et al., 
2007; Massey et al., 2008). There is evidence that this structure regulates neuronal plasticity 
(Pizzorusso et al., 2002), protects encapsulated neurons (Bruckner et al., 1999) and supports 
ion homeostasis (Bruckner et al., 1993). This observation is consistent with other reports that 
PNN digestion by chABC leads to increased plasticity and functional improvement due to 
reinnervation and sprouting; PNN breakdown in the cuneate nucleus promoted collateral 
sprouting/plasticity, resulting in axonal sprouting in the forelimb afferents after SCI (Massey 
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et al., 2006) and increasing plasticity in the spinal cord improved peripheral nerve 
regeneration (Galtrey et al., 2007). CSPG removal by chABC delivery in the adult visual 
cortex to treat monocular deprivation increased ocular dominance plasticity by significant 
recovery of dendritic spine density (Pizzorusso et al., 2006). In this study we observed that 
the PNN breakdown around the lesion area after chABC treatment (Fig. 4.5); motor neurons 
and many interneurons are surrounded by PNNs. It may possibly have caused the increased 
sprouting of serotonergic fibers, thereby increasing plasticity of spinal locomotor circuits and 
resulting in functional locomotor recovery.  
The de-stabilized PNNs by chABC digestion would promote anatomical plasticity by 
increasing the density of newly-grown processes in the adult CNS ECM, and it could lead 
functional plasticity. chABC-induced plasticity, such as collateral sprouting (Massey et al., 
2006) or aberrant sprouting (Barritt et al., 2006), is one major mechanism of chABC 
treatment. Therefore, possible negative effects are aberrant sprouting and neuropathic pain 
due to the aberrant plasticity (Woolf and Salter, 2000) or autonomic dysreflexia due to 
increased plasticity (Weaver et al., 2006). These concerns have been raised previously. 
Studies reported that no evidence of hyperalgesia was observed after chABC injection in to 
the spinal cord (Pizzorusso et al., 2006), and no increase of connectivity of nociceptive 
neurons and development of mechanical allodynia or thermal hyperalgesia was observed 
even after aberrant sensory fiber sprouting (Barritt et al., 2006). Therefore, it is very 
important to balance between detrimental sprouting and beneficial sprouting, and the 
molecular mechanism involved in chABC-mediated improvement of plasticity needs to be 
proven to develop the optimized chABC treatment after SCI. 
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In the short term study, there appears to be significant impact of chABC digestion at 2 
weeks, though evidence of functional recovery for in vivo studies was not seen until at least 6 
weeks. With regard to the time lag between peak CSPG deposition and first evidence of 
functional recovery, axonal regrowth and sprouting can occur after CSPG digestion – hence 
the lag in time between CSPG digestion and functional recovery. After injury, severed axons 
retract from the lesion site, therefore, functional recovery requires axonal regrowth and 
sprouting to reconnect/regain the functional pathway. Once our chABC treatment removes 
inhibitory molecules (CSPGs), the CSPG/astroglial-inhibitory region becomes permissive for 
axonal outgrowth, and axons can then regrow and sprout through the region. After SCI, 
animals are typically allowed 6 weeks or longer to assess axonal regeneration and functional 
recovery.  
Our data is consistent with other studies where successful digestion of CSPGs does 
not automatically lead to improved behavioral outcomes (Barritt et al., 2006; Cafferty et al., 
2007). Transgenic mice having a gfap promoter to express chABC demonstrated almost 
complete CSPG digestion at the reactive astrocyte-region. Significant sensory axon sprouting 
was observed, however it was not sufficient to improve motor function (Cafferty et al., 2007). 
It suggests that providing a permissive environment by removing inhibitory components is 
not enough to induce significant functional improvement; combination therapy needs to 
provide to favorable environment for sufficient axon regeneration. When chABC delivery is 
combined with NT-3 lentivirus delivery, dramatically increased axonal extension was 
observed compared to single delivery of chABC or NT-3 (Massey et al., 2008). In this study, 
combination treatment of chABC and NT-3 resulted in significantly increased axonal 
sprouting as compared to a single treatment of each.  
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To apply this method as a clinical therapy, the practicality of chABC treatment 
needs to be considered.  In this study, the chABC activity was limited to 1 mm away 
from lesion site and it is not clear whether this area is large enough to be clinically useful. 
Because chABC is a relatively large molecule, diffusion through neural tissue and 
extracellular space is limited. However, we believe that compared to intrathecal delivery 
of chABC by a mini-pump, chABC delivered via the hydrogel-microtube system diffuses 
deeper into the tissue (up to 1mm). This is because mini-pump delivery affects a larger 
region, diluting the chABC, whereas our delivery system enables local delivery into the 
tissue.  As CSPG deposition tapers off exponentially from the lesion border, the local 
delivery of chABC is relevant and effective, and sufficient diffusion (again as evident 
from our 6 week CS-56 staining) occurs to effectively digest the CSPGs deposited near 
the lesion site.  In humans, there might be a need for greater diffusion distances as the 
CSPG deposition zone may be deeper, but whether or not chABC diffusion into injured 
human cord will be a limitation or not remains to be determined. The minimum clinically 





In conclusion, we demonstrate that sustained local delivery of thermostabilized 
chABC digests CSPGs after SCI without aggravating secondary injury response. 
Combination therapy of chABC and NT-3 facilitated by our sustained delivery system 
enhanced axonal sprouting and functional recovery after SCI. This approach elegantly 
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obviates the need for invasive, indwelling catheter/pump-mediated delivery of chABC, 
enables combinatorial therapy with neurotrophic factors, and represents a promising 
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CONCLUSION AND FUTURE PERSPECTIVES 
 
Our delivery method of chABC provides an alternative treatment to spinal cord injury. 
The results showed enhanced axonal sprouting around the lesion site and improved 
functional recovery in locomotion. However the ultimate goal is to develop treatment 
strategies to promote axonal regrowth through the lesion site to regain functional pathways, 
and apply this method for clinical treatment. In this study no axon enters the lesion site and 
complete functional recovery was not achieved yet. Therefore, further studies will be 
discussed in this chapter to overcome these challenges.  
 
6.1 OPTIMIZATION OF CHABC TREATMENT FOR CLINICAL APPLICATION 
To investigate clinical relevance of our method, we need to optimize chABC 
treatment. There are several factors that need to be investigated and determined in order to 
design the optimized chABC administration: 1) characterize release profile of chABC with 
various concentrations of chABC, 2) different lengths of lipid microtube, and 3) then 
determine total amount of chABC for a certain delivery period. 
 For example, with our delivery method the chABC activity was limited to 1 mm 
away from lesion site and it is not clear whether the area is a large enough to induce axonal 
sprouting and functional improvement in clinical study. Because chABC is a relatively large 
molecule, diffusion through neural tissue and extracellular space is limited. chABC delivered 
via the hydrogel-microtube system has advantages and diffuses deeper into the tissue (up to 
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1mm) compared to intrathecal delivery of chABC. However in humans, there might be a 
need for greater diffusion distances as the CSPG deposition zone may be deeper and larger, 
but whether or not chABC diffusion into injured human cord will be a limitation remains to 
be determined. The minimum clinically relevant chABC concentration required to elicit 
behavioral recovery also remains to be determined. 
 
6.2 EFFECTS OF CHABC ON NERVE TISSUE AND IMMUNE SYSTEM 
In this study, single injection of chABC and sustained delivery of chABC did not 
increase inflammatory response compared to other controls (no treatment and P‟ase delivery) 
after injury. However the effects of chABC on nerve tissue and immune system need to be 
considered. When chABC was delivered intrathecally to intact spinal cord, robust sprouting 
of descending projects and primary afferents were observed (Barritt et al., 2006). However, 
in that study, it did not lead an increase in mechanical allodynia (noxious response to a 
usually non-painful stimulus) or thermal hyperalgesia (increased sensitivity to thermal pain). 
Other studies also reported that intrathecal delivery of chABC (0.2 ~ 1 ml of 200 U/ml) 
showed any morphologic changes in the spinal cord and any neurophysiologic changes in 
tibial nerves in rabbits (Olmarker et al., 1991). No adverse effects on nerve tissue and blood 
vessels were observed after intrathecal delivery in pig except a slight intrathecal fibrotic 
reaction (Olmarker et al., 1996). In those studies, they expected that approximately 1/40 
diluted concentration of chABC might be used clinically for chemonucleoysis: however, as 
we mentioned previously, the clinically relevant dosage still needs to be determined. 
chABC is an enzyme produced from bacteria, so there is a chance to evoke immune 
response. In this study, chABC was delivery locally at the lesion site with lipid microtube 
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and hydrogel, however antigenicity and immunogenicity of chABC and the delivery system 
still need to be tested. The safety test of chABC for side effects on nerve tissues and immune 
response needs to be investigated with the relevant dosage range for clinical application and 
sustained delivery system for prolonged delivery period.     
   
6.3 LONGER MICROTUBE: OPTIMIZATION OF DELIVERY VEHICLE 
A prolonged sustained delivery would be clinically desirable as increasing the 
duration of release agents. To prolong the period of sustained delivery, longer lipid 
microtubes can be considered as a delivery vehicle in vivo. The length and properties of 
microtube can be controlled by modifying a cooling procedure, varying concentration of lipid 
solution and changing ratio between ethanol and water for the solution to dissolve lipid 
(Lando et al., 1990; Thomas et al., 1995; Meilander et al., 2001). With the original protocol, 
average 37 micron length of microtube is fabricated. The adjustments were made to the 
original protocol. 70% ethanol and 1 mg lipid per 1 ml ethanol solution were fixed and a part 
of cooling process modified; the rate of decreasing temperature (53-23 deg) changed from 
1deg/40min to 1 deg/10 min. The measured average length of microtube was approximately 
100 micron (Fig. 6.1). We demonstrated that the length of microtube is controllable and since 
the release profile of loaded agents is dependent on the length of microtube, it facilitates to 
control drug delivery. The release duration and rate of agent from the delivery scaffold also 
can be controlled by modifying the gel. The release profiles are dependent on the type and 




Figure 6.1. Histogram of microtube length distribution with a modified 
fabrication procedure. The average length is about 100 µm.  
 
 
6.4 OPTIMIZATION OF DOSAGE  
 In this in vivo study presented in Chapter 4 and 5, one concentration/total amount of 
chABC and NT-3 was delivered to examine the effect on levels of CSPG deposition, axonal 
regeneration and functional recovery after SCI in rats. We demonstrated that there are 
significant differences in CSPG digestion, axonal sprouting and functional recovery between 
single injection and sustained delivery. Some other studies reported that there is no 
significant difference in sprouting axons between chABC treatment and untreated groups 
after SCI (Iaci et al., 2007). This implicates that the amount/concentration of delivered 
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and behavioral recovery. Therefore, it is necessary to conduct experiments to optimize the 
concentration and total amount, and delivery period. The optimal dosage delivered in 
combination of chABC and NT-3 also needs to be determined, because combining each 
optimal dosage for individual delivery of chABC or NT-3 might not be the best possible 
dosage for the combination therapy. For example, other study showed that dramatically 
improved (~40 times) axonal sprouting was observed with combination therapy of chABC 
and NT-3 (Massey et al., 2008). In this long term in vivo study, even more enhanced axonal 
sprouting and functional recovery were observed in chABC/NT-3 treated animals than 
individually treated animals. If the concentration and ratio between chABC and NT-3 are 
modified, it could synergistically enhance effects on axonal regeneration.  
 
6.5 LONGER IN VIVO STUDY 
 To evaluate the effects of chABC two animal studies were conducted; a 2 week 
study to evaluate of functionality of our chABC-delivery system in Chapter 4 and a 6 week 
study to examine axonal sprouting/regeneration and functional recovery as discussed in 
Chapter 5. The duration of the in vivo study is a critical factor to determine whether the 
administrated therapy is effective or not to treat injuries or diseases. For example, in this 
study if we had terminated earlier than 6 weeks, we would not observe the significantly 
improved functional recovery in locomotion assessed by stride length between animal groups. 
Similarly, if we conduct longer period animal study, such as 8 or 12 weeks, more fibers 
might outgrow closer to the lesion and even completely grow through/around the lesion site 
to reconstruct synaptic connections. This would lead to improvement of more precise 
locomotion controls.  
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6.6 RATE AND AMOUNT OF CSPG DEPOSITION IN VIVO AFTER SCI 
 In the in vivo study, significant differences were observed in the CS-56-IR and 3B3-
IR intensity at 2 weeks, and CS-56-IR intensity at 6 weeks between the chABC-hydrogel-
microtube treated groups and controls. These results suggested that the enzyme, chABC, still 
retains its enzymatic activity after being released from the hydrogel-microtube delivery 
scaffold in vivo, and digests CSPGs more effectively than the controls, chABC-hydrogel or 
chABC-single injection treated groups. However, it is not clear how constant the enzymatic 
activity of released chABC remains over this time period and how much chABC is released 
from the delivery scaffold and diffused into the tissue. Once chABC is released from the 
hydrogel-microtube delivery scaffold, it can be assumed that the activity of chABC will be 
similar to fresh, unstabilized chABC, because the ratio of trehalose to chABC becomes a lot 
diluted. It is shown that the production of several CSPGs is differentially regulated following 
spinal cord injury (Jones et al., 2003) by immunohistological analysis. However, the rates 
and amount of CSPG deposition are not known and depend on injury models, degree of 
injury and age (Gilbert et al., 2005). Therefore, it would be clinically desirable if the CSPG 
deposition rate can be determined for specific injury models and degree of injury.  
 
6.7 COMBINATION STRATEGIES: CHABC AND STEM CELL TRANSPLANTATION   
This study showed that combination therapy with thermostabilized chABC and NT-3 
significantly enhanced axonal sprouting and functional recovery. Our hydrogel-microtube 
delivery system with thermostabilized chABC could provide permissive environment for 
neurite outgrowth and can be combined with other strategies, such as delivery of 
neurotrophic factor, cell transplantation (NSC, olfactory, Schwann cell, autologus peripheral 
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nerve graft, etc), and acellular scaffold implantation. This combination therapy can be a 
potent treatment for many neurodegenerative diseases by promoting axonal regeneration and 
restoring complete functional recovery after neuronal injuries. One cell transplantation 
strategy, neural stem cell (NSC) therapy, is very promising; however, this approach needs to 
be further elucidated before proceeding with clinical trials.  
Factors regulating NSC have been investigated, and studies showed that the 
modulation of local environment is important in regulating NSC. Evidences have been 
provided that CSPGs regulate neural stem/progenitor cell proliferation and intervene in fate 
decision making between the neuronal and glial lineage. In vitro experiments showed that 
CSPGs inhibit migration of neural stem/progenitor cell (NSPC)-derived cells and chABC 
treatment attenuated the inhibitory effect (Ikegami et al., 2005; chABC). Also, cell-surface 
soluble GAGs involve in internalization of extracellular proteins for some progenitor cell to 
facilitate differentiation; an example would be of heparin sulfate proteoglycan for pancreatic 
stem cells (Ueda et al., 2008; heparin). As explained above, chABC can be used to modify 
the local environment in CNS via digesting CS-GAGs and also to selectively degrade GAGs 
for investigating biological roles of CSPGs in vitro.  
The use of NSCs in conjunction with chABC may prove to be therapeutic in repairing 
CNS by modulating cellular matrix and CSPGs, which act as a barrier for stem cell migration 
after transplantation. In many cases, however, transplanted stem cells fail to migrate and 
integrate into the host tissue and CSPGs are considered as a putative inhibitor of stem cell 
migration in vivo. chABC treatment combined with NSPC transplantation into injured spinal 
cord promoted migration of the transplanted cell into the host spinal cord and resulted in 
increased sprouting of growth-associated protein -43-positive fibers at the lesion site 
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(Ikegami et al., 2005; chABC). When Müller stem cells were implanted with chABC into 
degenerating  retina , this resulted in dramatic increase of migration of stem cell into all of 
the retina cell layers (Singhal et al., 2008; CSPGs; Fawcett) and differentiation into retinal 
neurons and glia (Bull et al., 2008; glaucoma stem). 
Studies suggest that chABC treatment can facilitate migration and differentiation of 
transplanted NSPCs. Therefore, when the sustained local delivery of thermostabilized 
chABC by our hydrogel-microtube system is combined with NSPCs transplantation, it will 
be a promising strategy for the regeneration of injured or degenerated CNS tissues. Also, our 
chABC treatment can be combined with delivery of other neurotrophic factors and cell 
transplantations.  
 
6.8  DIFFERENCES BETWEEN HUMAN CASES AND RAT INJURY MODEL 
It is hard to simulate the human cases of SCI in animal experiments: first, human SCI 
occurs in the closed vertebral system generally under conscious state and a combination force 
of flexion, extension, rotation and compression works on the cord when the injury happens 
(Sharma et al., 1993; Choi, 1996). Most human SCI results from fracture of vertebral column 
or luxation of vertebrae. In contrast, in animal models, injury or compression is always 
conducted on the posterior side of the cord with laminectomy (opened vertebra system) under 
anaesthetized state and one force, such as contusion, compression or incision, is applied to 
produce injury for high reproducibility (Sharma, 2005a). Therefore, human SCI cases are 
more complex and only few cases are similar to experimental models in terms of the 
magnitude and severity of the injury (Sharma, 2005b; Onifer et al., 2007). Table 3 
summarizes different facts between human and rat spinal cord.  
139 
 
Parameters Human Rat 





Length (cm) 43-45 8-10 
Weight (g) 34 0.7 
Proportion to brain 
(volume %) 
2 35 
Glial/neuron ratio 12-16 10-14 




Table 3. A comparison between human and rat spinal cord.  
* Weight for rat SCI is about one fifth to human SCI. Table from 
Sharma, 2007.  
 Our study required an SCI model allowing for behavioral and immunohistological 
analysis to examine functional recovery and axonal regeneration. There are several 
commonly used models for spinal cord injury and each has advantages and disadvantages: 
complete spinal transection, dorsal over hemisection, lateral hemisection injury, compression 
and contusion.  
The complete transection model removes any overlap between spared and regenerated 
fibers. However, the animal undergoes severe pain and various syndromes, such as bowel 
and bladder dysfunction and no functional recovery with hindlimbs, because the transection 
completely eliminates functions below the injury site. Therefore, it requires relatively long 
term management with various post-surgical complications and morbidity is higher than 
other injury models.  
The contusion model could be the most clinically relevant model, although it still 
lacks some of the absent factors described above. A fluid filled cyst forms at the impacted 
area and is surrounded by tissue containing spared/intact axons (Kwon et al., 2002). Because 
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of the spared axons around the cyst, it is hard to distinguish between spared and regenerated 
axons (Steward et al., 2003) and it is a limitation for studies focusing on regeneration.  
The lateral transection model is a complete transection of one side of the spinal cord. 
In this model all pathways in one side of the cord are severed. However, intact axons in the 
non-lesioned side can sprout into the lesioned side and make it hard to distinguish from 
regenerated axons (Kwon et al., 2002).  
The dorsal over hemisection model has relatively moderate severity of injury. In this 
injury model, damage is limited in the dorsal column and animals undergo less stress and 
pain with less post-surgery dysfunctions than other injury models. Axonal regeneration can 
be easily quantified by injection of anterograde tracer (i.e. BDA) to the corticospinal tract 
(CST) or retrograde tracer to the primary sensory pathway (i.e. cholera toxin subunit B), and 
spared fiber is not a critical issue. Therefore, the dorsal over hemisection model was chosen 
for our study. There is a chance of spared fibers in the bilateral transected CST (Vavrek et al., 
2006), and the primary sensory pathway was chosen in this study to examine regenerating 
axons.   
As a further study, contusion injury model can be used to examine the delivery 
efficiency of our topical delivery method with chABC and develop a more relevant delivery 
method for human therapy. In the contusion model, it would be difficult to deliver drugs deep 
through the surrounding tissue to the cyst with our topical delivery model if the drug is not 
small enough. Diffusion efficiency of chABC needs to be examined in this model. If the 
diffusion is not enough to remove CSPGs and promote axonal outgrowth, alternative delivery 
methods should be developed, such as a direct injection of mitcrotube-trehalose/chABC into 
the cyst by needle. 
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